

DCTD TUMOR REPOSITORY

A CATALOG OF *IN VITRO* CELL LINES AND
TRANSPLANTABLE ANIMAL AND HUMAN TUMORS

Maintained for the Division of Cancer Treatment and Diagnosis
National Cancer Institute

Sponsored by:

Biological Testing Branch
Developmental Therapeutics Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health

Maintained by McKesson Bioservices for
The National Cancer Institute at Frederick
Bldg. 1073
Frederick, Maryland 21702-1201

www.dtp.nci.nih.gov

UPDATED: June 2003

DCTD Tumor Repository

Table of Contents

	Page
INTRODUCTION	4
ORDERING PROCEDURES	5
MATERIAL TRANSFER AGREEMENT	6
SHIPMENT OF TUMORS	8
SUBMISSION OF TUMORS FOR CRYOPRESERVATION	8
MOUSE TUMORS FROM THE JACKSON LABORATORY	8
FREEZING PROCEDURE	9
RECOMMENDED THAWING PROCEDURE	9
BACTERIAL AND VIRAL MONITORING OF CRYOPRESERVED TISSUE	10
<i>IN VITRO</i> ESTABLISHED CELL LINES	10
A. Quality Control and Characterization	10
B. Freezing and Storage	10
C. Recommended Procedure for Thawing Frozen Cell Cultures	10
Human Tumors	12
Human <i>In Vitro</i> Established Cell Lines are on pages 57-60	
Hamster Tumors	18
Guinea Pig Tumors	20
Mouse Tumors	22
Addendum A: Mouse Tumors Listed by Histologic Type	23
Addendum B: Mouse Tumors Listed by Host Strain	25
Addendum C: Drug-Resistant Murine Leukemias and Treatment Information	27
Mouse Tumors from the Jackson Laboratory	42

Table of Contents (Continued)

INVENTORY

	Page
Rabbit Tumors	45
Rat Tumors	47
Rat Tumors from Dr. Robert Noble (Endocrine Responsive)	52
<i>In Vitro</i> Established Cell Lines	56
Human <i>In Vitro</i> Cell Lines	57
Non-human <i>In Vitro</i> Cell Lines	65
NCI Anti-Cancer Cell Line Panel	61
Yeast Strains	66
Index	68

INTRODUCTION

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute, has maintained since the early 1960s a low temperature repository of transplantable *in vivo*-derived tumors and *in vitro*-established tumor cell lines from various species. Currently located at the National Cancer Institute at Frederick in Frederick, Maryland, the DCTD Tumor Repository* serves as a resource for viable, contaminant-free experimental tumor lines, many of which are not obtainable elsewhere. The Repository makes these materials available to qualified investigators as a service to the research community.

The Repository's tumor collection contains a wide variety of frozen types of human and animal origin. Virtually all of the human tumors are xenografts grown in athymic nude mice, although there are some that grow in conditioned rats or in hamster's cheek pouch. Several mouse leukemia lines in the collection are resistant to single drugs of varying modes of action. Multidrug-resistant lines are also available. In addition, the collection includes variant sublines of B16 melanomas that exhibit a different degree of metastasis to various organs.

The tumors in this catalog are categorized by species, namely, human, hamster, guinea pig, mouse, rabbit and rat. Within animal species, the list is in alphabetical order by tumor designation. Tumors with numeric designations are listed at the end. Human tumors are grouped by tumor type.

We request that the DCTD Tumor Repository, National Cancer Institute at Frederick, Frederick, Maryland, be cited in publications as the source of tumor materials. We also request that reprints of publications be furnished to the Repository.

*Previous contract locations of the Tumor Repository include Microbiological Associates, Inc., Bethesda, MD; Arthur D. Little, Inc., Cambridge, MA; and Mason Research Institute, Worcester, MA.

ORDERING PROCEDURES

Tumor materials are furnished to qualified investigators affiliated with recognized research laboratories *only*. Items required to complete an order are:

- a. **Original letter of request**, typed on official Institutional Letterhead
- b. **Purchase Order**, or indicate payment by credit card, wire transfer or other
- c. **Two Material Transfer Agreements (MTA's)**, each with **original signatures from both the requestor and authorizing official** at your institution (required by NCI).

Request will be processed only after receiving the above three items. Faxed MTA's cannot be accepted. **All completed paperwork must be returned via Mail or Courier to:**

Katherine Gill	E: gillk@mail.nih.gov
Biological Testing Branch	T: 301-846-5483
DTP, DCTD, NCI-Frederick	F: 301-846-6183
Fairview Center, Suite 205	
1003 West 7th Street	
Frederick, MD 21701-8531	

The letter should specify the material desired and should include a summary statement concerning the objectives of the studies in which the requested materials will be used. Completed MTA's for the material ordered should be enclosed with the letter, unless a current MTA is already on file for the same item(s). MTA's are valid for a period of three years.

Multiple cell lines, tumor lines, or yeast strains can be ordered using a single MTA. Each must be clearly identified under #1 on MTA or through use of an addendum.

Additional requests by the same investigator for previously received material should indicate the date and MTA number of the earlier MTA submission. Newly requested material will require completion of a separate MTA.

The following fees will be charged to help defray the cost of maintaining the facility. Payment can be arranged by credit card, wire transfer, invoicing or purchase order.

Cell or Tumor Lines:

	<u>Domestic & Canadian</u>	<u>Foreign</u>
One frozen vial	\$150.00	\$250.00
Each additional vial with same shipment	\$ 75.00	\$ 75.00

Yeast Strains:

	<u>Domestic & Canadian</u>	<u>Foreign</u>
One strain	\$150.00	\$ 250.00
Each additional strain with same shipment	\$ 75.00	\$ 75.00
Complete set (16 strains)	\$900.00	\$1000.00

Foreign recipients should obtain applicable import permits, if required, and send a copy with order. Shipments to foreign countries will be charged at the prevailing rates.

Material will be sent freight prepaid. An invoice for payment will follow.

Checks payable to: SAIC-Frederick, Inc.

Inquiries regarding availability and shipping should be directed to:

Jane Shelton	T: (301) 846-5025	F: (301) 846-6941	E: shelton@dtfax2.ncifcrf.gov
--------------	-------------------	-------------------	-------------------------------

All other questions should be directed to:

Richard Camalier	T: (301) 846-5607	F: (301) 846-6183	E: camalier@mail.nih.gov
------------------	-------------------	-------------------	--------------------------

National Cancer Institute

MATERIAL TRANSFER AGREEMENT-A Cell lines maintained in the NCI-DCTD Repository

This Material Transfer Agreement ("MTA") has been adopted for use by the National Cancer Institute ("NCI") for transfers of cell lines from the Division of Cancer Treatment and Diagnosis ("DCTD") Tumor Repository ("Research Material"). The DCTD Tumor Repository has maintained, since the early 1960's, a low temperature repository of transplantable tumor and tumor cell lines from various species. The Repository serves as a resource for experimental tumor lines from various species, many of which are not obtainable elsewhere. The Repository makes these Materials available as a service to the Research Community.

Recipient: _____
Name of Recipient Investigator and Recipient Institution

1. NCI agrees to transfer to Recipient named above the following Research Material:

(use an attachment page if necessary)

2. **THIS RESEARCH MATERIAL MAY NOT BE USED IN HUMAN SUBJECTS.** The Research Material will only be used for research purposes by Recipient's investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for commercial purposes such as production or sale. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material. These samples are being provided in a manner that does not allow for direct identifiable patient information to the Recipient, and therefore do not constitute Human Subject Research as defined in 45 CFR Part 46, "Protection of Human Subjects".

3. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows (use an attachment page if necessary):

4. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge NCI's contribution of this Research Material unless requested otherwise. To the extent permitted by law, Recipient agrees to treat in confidence, for a period of three (3) years from the date of its disclosure, any of NCI's written information about this Research Material that is stamped "**CONFIDENTIAL**," except for information that was previously known to Recipient or that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation. Any oral disclosures from NCI to Recipient shall be identified as being **CONFIDENTIAL** by notice delivered to Recipient within ten (10) days after the date of the oral disclosure. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if NCI has given **CONFIDENTIAL** information to Recipient such public disclosure may be made only after NCI has had thirty (30) days to review the proposed disclosure to determine if it includes any **CONFIDENTIAL** information, except when a shortened time period under court order or the Freedom of Information Act pertains.

5. This Research Material represents a significant investment on the part of NCI. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under her or his direct supervision without advance written approval of NCI. NCI reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed or three (3) years have elapsed, whichever occurs first, the Research Material will be disposed of as directed by NCI.

6. This Research Material is provided as a service to the research community. IT IS BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.

7. Recipient may retain title to the patent rights in inventions made by its employees in the course of the Research Project. Recipient agrees not to claim, infer, or imply Governmental endorsement of the Research Project, the institution or personnel conducting the Research Project or any resulting product(s). Unless prohibited by law from doing so, recipient agrees to hold the United States Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of the Research Material.

8. The undersigned Recipient expressly certifies and affirms that the contents of any statements made herein are truthful and accurate.

9. This MTA shall be construed in accordance with Federal law as applied by the Federal courts in the District of Columbia.

Date: _____
Recipient **Investigator's Signature and Title**

Date: _____
Authorized Signature and Title, for Recipient's Institution (**Note:** Authorized Signature has the authority to bind the Institution to the terms of this Material Transfer Agreement)

➔ Recipient's Shipping Address:

➔ Recipient's Phone, Fax, Email:

Date: _____, Richard Camalier, BTB, DTP, NCI-Frederick
Authorized Signature for NCI

NCI's Mailing Address:

Katherine Gill
Biological Testing Branch
DTP/DCTD/NCI
Fairview Center, Suite 205
1003 W. 7th Street
Frederick, MD USA 21701-8531

Phone: 301.846.5483
Fax: 301.846.6183
Email: gillk@mail.nih.gov

SHIPMENT OF TUMORS

The transplantable tumors are distributed as frozen vials of tumor tissues or cell suspension. Transplantable tumors as well as cell culture lines are shipped as frozen vials of tissues on dry ice. Each tumor shipment includes an information sheet showing, among other items, the proper tumor designation, cryopreserved date, *in vivo* host, etc.

Requested tumors are shipped two to three weeks after receipt of all completed paperwork. Domestic shipments leave the Repository no later than Wednesday in order to reach their destination on week days. Foreign shipments are sent according to final destination. Before shipment, the Repository notifies the Recipient of the waybill number and carrier information by e-mail or fax. Recipient must notify the Repository or make arrangements for receipt of the tumor lines, in the event that they will not be available to receive the shipment. An invoice for payment will follow and payment is due upon receipt.

SUBMISSION OF TUMORS FOR CRYOPRESERVATION

Investigators who have unique and novel experimental tumor lines and wish to submit their tumors to the Repository for cryopreservation and storage should write a letter of intent to the Project Officer. Upon acceptance, the Project Officer will inform the investigator in writing, and will provide instructions on the procedure for shipping tumor materials to the Repository. Tumor tissues or cells (frozen or ambient) are preferred over tumor-bearing animals.

At the Repository, the tumor line(s) will be tested for viral and bacterial contamination. When proven "clean," the line(s) will be expanded, *in vivo* or *in vitro* as appropriate, for large batch cryopreservation. Viability and growth of the frozen tumors will be evaluated. The tumors will be included in the Repository's inventory, and upon joint approval of the submitting investigator and the Project Officer, they will be made available for distribution to the scientific community.

MOUSE TUMORS FROM THE JACKSON LABORATORY: These tumors formerly were maintained and distributed by the Jackson Laboratory. The list of available tumors begins on page 39 of the DCTD Tumor Repository Catalog. They were cryopreserved at EG&G Mason Research Institute and are distributed only as vials of frozen tumor tissue. The required host animals for carrying the JAX tumors in serial transplantation may be obtained from:

Animal Resources
The Jackson Laboratory
600 Main Street
Bar Harbor, ME 04609
USA
T: 800.422.MICE
207.288.5845
F: 207.288.6150

FREEZING PROCEDURE

Solid tumors are frozen as 2 x 2 x 2 mm fragments suspended in a freezing medium. Ascites or tissue culture cells are frozen as single cell suspension at a concentration of 10^6 - 10^7 cells per ml. The freezing medium consists of appropriate tissue culture growth medium plus 10% DMSO and 10% fetal bovine serum.

Aseptically harvested ascites tumors are diluted in the freezing medium at a concentration of 10^6 - 10^7 cells per ml. One ml suspension is pipetted into each 2 ml vial (Nunc cryotube). The vials are screw-capped tightly and labeled with Repository number. Tissue culture cells are prepared in a similar manner. For solid tumors, the aseptically excised tumor tissue is cut into 2 x 2 x 2 mm fragments after freeing it of necrotic materials. The fragments are placed in vials containing 1.5 ml of freezing medium.

The processed tumors are frozen initially in a controlled slow-rate freezing apparatus at the rate of 0.5°C per minute to -20°C and 1°C per minute to -80°C. The frozen vials are stored in specific locations in the liquid nitrogen freezers in the Repository after the controlled freezing cycle.

RECOMMENDED THAWING PROCEDURE

Frozen tumor cells or tissues received from the Repository should be kept frozen at -70°C or lower until ready for use. For prolonged storage (more than two days), liquid nitrogen freezers are recommended.

The vials in which the cell lines are stored are reliable; however, they are very susceptible to contamination if thawed in a contaminated water bath. Thawing should be rapid, i.e., within 60-90 seconds. Place the vial in a warm water bath at 37-40°C and agitate vigorously to thaw. Immerse the vial in 70% ethanol before uncapping. Implant immediately after thawing. The concentration of DMSO is not toxic to tissues and implantation may be made directly from the vial.

For tissue culture, transfer the contents of the vial into a petri dish or a flask containing at least 10 volumes of the recommended culture medium and incubate. In order to remove the protective freezing additive (DMSO) from the culture medium, we suggest that the culture medium be changed 24 hours after seeding. If it is desired that DMSO be removed immediately, centrifuge the diluted suspension at approximately 125 x g for 10 minutes, discard the supernatant, and resuspend the cells in an appropriate volume of growth medium.

CAUTION: We strongly recommend wearing protective glasses or face shields when thawing tissues in glass vials.

TUMOR TRANSPLANTATION: It is recognized that transplantable tumor systems are experimental tools for investigators in scientific disciplines other than tumor biology or transplantation immunogenetics. Therefore, we encourage investigators with limited transplantation experience to contact the Tumor Repository for more detailed information on techniques.

BACTERIAL AND VIRAL MONITORING OF CRYOPRESERVED TISSUES: In addition to testing all freeze-runs for bacterial contamination, cryopreserved tissues are tested for viral contamination by the MAP test. The viruses tested for are as follows: pneumonia virus of mice (PVM), reo virus-type 3 (Reo 3), Theiler's virus, murine encephalitis (GD VII), polyoma (Poly), minute virus of mice (MVM), mouse hepatitis virus (MHV), lymphocytic choriomeningitis (LCM), Sendia virus (Send), ectromelia, mouse pox (Ectro), lactic dehydrogenase virus (LDH).

IN VITRO ESTABLISHED CELL LINES:

- A. Quality Control and Characterization - The quality control and characterization procedures for the incorporation of new cell lines into the Tumor Repository are as follows: Upon receipt, each cell line is immediately transferred to fresh antibiotic-free medium and cultured for one week, after which it is tested for mycoplasma (PPLO) contamination. Standard culture procedures under aerobic and anaerobic conditions, as well as the orcein staining procedure of Fogh, are used. The PPLO medium is extremely rich, and this procedure will also detect most bacterial and fungal contaminants.
- B. Freezing and Storage - The cell cultures are frozen in ampules containing 1.0 ml of cell suspension at $2-6 \times 10^6$ cells/ml in fresh culture medium containing 10% DMSO. Freezing is performed as on page 6. Twenty-four hours after freezing, a representative ampule is removed, thawed, and viable cell count is performed, using the trypan blue dye exclusion procedure. The culture is also tested for its ability to initiate a heavy viable culture. Cell preparations which show less than 50% viability or poor growth are discarded and a new lot is prepared.
- C. Recommended Procedure for Thawing Frozen Cell Cultures - The vials in which the cell lines are stored are reliable; however, they are very susceptible to contamination if thawed in a contaminated water bath. The following procedures are provided to eliminate this problem.

Remove the ampule from the dry ice container and place it directly into a 37-40°C water bath (or vessel) of freshly drawn water containing an effective concentration of disinfectant. The thawing should be vigorous and rapid (within 40-60 seconds). As soon as the thawing is complete, remove the ampule from the water bath and immerse in 70% ethanol at room temperature. All of the operations from this point should be carried out under strict aseptic conditions in a sterile room, cubicle, or hood.

Transfer the contents of the ampule (1 ml volume) into a 100 mm petri dish or 25 cm² flask containing 8-10 ml of the recommended culture medium, and incubate at the appropriate temperature and carbon dioxide level.

In order to remove the protective freezing additive (DMSO) from the culture medium, we suggest that the culture medium be changed 24 hours after thawing. If it is desired that the freezing additive be removed immediately or that a more concentrated cell suspension be obtained, centrifuge the above diluted suspension at approximately 125 x g for 10 minutes, discard the fluid, and resuspend the cells in an appropriate volume of growth medium.

HUMAN TUMORS

SPECIES: HUMAN			
Tumor Designation	Histologic Type	General Information	Species and/or Strain of Transplantability
BREAST			
COO-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
DU4475	Mammary Carcinoma	Primary explant from cutaneous tumor nodule in region of mastectomy established <i>in vitro</i> by Dr. A.J. Langlois, Duke University Medical Center; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
ELL-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
HIG-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
MCF/7	Mammary Carcinoma	Primary explant from pleural effusate established <i>in vitro</i> by Dr. H.D. Soule, Michigan Cancer Foundation; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MDA-MB-436	Mammary Carcinoma	Primary explant from pleural effusate established <i>in vitro</i> by Dr. Relda Cailleau, M.D. Anderson Hospital and Tumor Institute; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MX-1	Mammary Carcinoma	Primary xenotransplant from an infiltrating duct carcinoma (CLO-G). Adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
MX-2	Mammary Carcinoma	Adapted to <i>in vivo</i> from <i>in vitro</i> established pleural effusate.	Nude Athymic Mice
SW-613	Mammary Carcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
VAN-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
LUNG			
LX-1	Lung, undifferentiated carcinoma	Xenotransplant from a metastasis to subcutaneous tissue (DOY-G). The primary lung tumor was an oat cell carcinoma. Adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
COS-G	Lung, papillary carcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice

SPECIES: HUMAN			
Tumor Designation	Histologic Type	General Information	Species and/or Strain of Transplantability
LUNG (continued)			
H-MESO-1	Lung, mesothelioma	Xenotransplant from a primary tumor received from Dr. R.M. Williams and Dr. A. Rossini. Adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
H-MESO-1A	Lung, mesothelioma	H-MESO-1 converted to ascites form by Dr. A.E. Bogden.	Nude Athymic Mice
NCI-H23 H23	Lung, nonsmall cell, adenocarcinoma	Obtained from Dr. Adi Gazdar.	Nude Athymic Mice
NCI-H460 H460	Lung, nonsmall cell, epid.	Obtained from Dr. Adi Gazdar.	Nude Athymic Mice
MRI-H-165	Lung, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-266	Lung, poorly differentiated carcinoma	Xenotransplant from a metastasis, adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
COLON			
CX-1 (HT-29)	Colon, adenocarcinoma	Primary, untreated adenocarcinoma (HT-29) adapted to <i>in vitro</i> cell culture by Dr. Jergen Fogh; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden. Secretes CEA.	Nude Athymic Mice
CX-2	Colon, carcinoma	Primary xenotransplant (CA-1) adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella. Received at MRI from Dr. A. Ovejera.	Nude Athymic Mice
CX-3	Colon, carcinoma		Nude Athymic Mice
CX-5	Colon, adenocarcinoma	Xenotransplant from an untreated metastasis (SQU-G) adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
GOB-G	Colon, adenocarcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
HCC-2998	Colorectal carcinoma	Obtained from Dr. I.J. Fidler.	Nude Athymic Mice
HCT-15	Colon, carcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
KLO-G	Colon, adenocarcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
KM20L2	Colon, adenocarcinoma	Obtained from Dr. I.J. Fidler.	Nude Athymic Mice
MRI-H-194	Colon, adenocarcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
LOVO I	Colon, adenocarcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice

SPECIES: HUMAN			
Tumor Designation	Histologic Type	General Information	Species and/or Strain of Transplantability
COLON (continued)			
LOVO II	Colon, adenocarcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
MRI-H-250	Colon, carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MELANOMA			
BOW-G	Melanosarcoma	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
DEAC-7	Melanoma	Received as cryopreserved ampules from Dr. S. Warren and Dr. W.B. Patterson.	Hamster Cheek Pouch
FO #1	Melanoblastoma	Adapted to <i>in vivo</i> transplantation (FOS-G) by Dr. B. Giovanella.	Nude Athymic Mice
NIS-G	Melanosarcoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
TRI-G	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
WIL-G	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
MRI-H-121B	Melanoma, malignant	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-187	Melanoma, epithelioid, melanotic	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-221	Melanoma, malignant	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-255	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
CERVIX			
MRI-H-130	Cervix, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-177	Cervix, squamous cell carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-186	Cervix, invasive, large cell, nonkeratinizing, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-196	Cervix, poorly differentiated squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice

SPECIES: HUMAN			
Tumor Designation	Histologic Type	General Information	Species and/or Strain of Transplantability
CERVIX (continued)			
MRI-H-215	Cervix, invasive, large cell, nonkeratinizing, poorly differentiated, epidermoid carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
KIDNEY			
MRI-H-121	Kidney, carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplant by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-166	Kidney, transitional cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
ENDOMETRIUM			
MRI-H-147	Endometrium, carcinoma, Müllerian duct	Primary xenotransplant adapted <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-171	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-220	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-253	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
OVARY			
MRI-H-207	Ovary, undifferentiated carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-227	Ovarian Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
MRI-H-258	Ovarian Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
MRI-H-273	Ovarian Carcinoma	Originated from metastasis. Established <i>in vivo</i> by Dr. A.E. Bogden. Received from New England Deaconess Hospital.	Nude Athymic Mice
MRI-H-1834	Ovarian Carcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
SWA-G	Ovarian Carcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovannella.	Nude Athymic Mice

SPECIES: HUMAN			
Tumor Designation	Histologic Type	General Information	Species and/or Strain of Transplantability
SARCOMA			
HS-1	Sarcoma	No historical information available.	Conditioned Rats
OGL-G	Sarcoma, spindle cell, periosteal osteogenic	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
DEL-G	Sarcoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
EPIDERMOID			
HEP-3	Epidermoid carcinoma	No historical information available.	Conditioned Rats
DEAC-1	Mucoepidermoid carcinoma	Received as cryopreserved ampules from Dr. S. Warren and Dr. W.B. Patterson.	Hamster Cheek Pouch
CNS			
SF 295	Glioblastoma	Obtained from Dr. Rosenblum.	Nude Athymic Mice
MISCELLANEOUS			
CWR-22	Prostate, adenocarcinoma	Received from Dr. T. Pretlow, <i>in vivo</i> cultivation requires testosterone supplementation. Not an <i>in vitro</i> cell line.	Nude Athymic Mice
DAU	Burkitt's lymphoma	Received from Dr. T. Griffin, adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-254	Stomach, adenocarcinoma	No historical information available.	Nude Athymic Mice
MRI-H-1579	Prostate Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. Blute, St. Vincent Hospital, Worcester, MA.	Nude Athymic Mice

Note: Human *In Vitro* Established Cell Lines are on pages 56-59.

HAMSTER TUMORS

SPECIES: HAMSTER				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Fibrosarcoma	Fibrosarcoma	Ascites	Not Specified	
H-12	Mesothelioma	Solid	Golden Syrian	
H-75	Mesothelioma	Solid	Golden Syrian	
Islet Cell	Pancreatic Adeno- carcinoma	Solid	Golden Syrian	
Lymphosarcoma	Lymphosarcoma	Ascites	Not Specified	
Melanoma	Melanotic Melanoma	Solid	Not Specified	
Pan #1 (Fortner)	Pancreatic Duct Adeno- carcinoma	Solid	Not Specified	
SB #1 (Fortner)	Small Bowel Adeno- carcinoma	Solid	Not Specified	
TG1-4	Mesothelioma	Solid	Golden Syrian	
TS1-4	Epidermoid Carcinoma	Solid	Golden Syrian	
10-24	Mesothelioma	Ascites	Golden Syrian	
1382J	Liver Carcinoma	Solid	Golden Syrian	
2309V	Pancreatic Islet β Cell Adenocarcinoma	Solid	Golden Syrian	
4671	Pancreatic Duct Adeno- carcinoma	Solid	Golden Syrian	Line B is insulin- secreting
6973P	Leiomyosarcoma	Solid	Golden Syrian	
8721R	Renal Carcinoma	Solid	Golden Syrian	
8746Q	Uterine Adeno- carcinoma	Solid	Golden Syrian	
9242 ₂	Parotid Acinar Cell Adenocarcinoma	Solid	Golden Syrian	
10838	Seminoma	Solid	Golden Syrian	
11348P	Pulmonary Squamous Cell Carcinoma	Solid	Golden Syrian	
11963V	Leiomyosarcoma	Solid	Golden Syrian	
22047	Adenocarcinoma	Solid	Golden Syrian	

GUINEA PIG TUMORS

SPECIES: GUINEA PIG				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Line 1	Hepatocarcinoma	Ascites	Strain 2	
Guinea Pig GP Line 10	Hepatocarcinoma	Ascites	Strain 2	
Nitrosamine-induced Hepatoma	Hepatoma	Solid	Strain 39	

MOUSE TUMORS

Two addenda have been inserted in this section to facilitate identification or selection of mouse tumors by histologic type (Addendum A) and by mouse strain (Addendum B). A third (Addendum C) is a list of drug-resistant murine leukemias together with treatment information.

ADDENDUM A

MOUSE TUMORS LISTED BY HISTOLOGICAL TYPE*

<u>Adrenal</u>	<u>Glioma</u>	<u>Lung</u>
AT	Glioma 26	ASB XIV
LAF ₁	Glioma 261	C4461
		CAD2
<u>Anaplastic Carcinoma</u>	<u>Hemangioendothelioma</u>	LC-12
dbrB (Jax)	36230 TLT	Lewis
	42021 TCT	M4898
<u>Bladder</u>	42022 TST	Madison
	42052 TST	Nettesheim
FCB	42076 TST	
	44316 TST	<u>Lymphoma &</u>
<u>Colon</u>	44347 TST	<u>Lymphosarcoma</u>
CA07/A		BL12
CA36/Ara C	<u>Hepatoma</u>	EL-4 Male
CA51	BW 7756 (JAX)	L18464
Colon 26	H6 (JAX)	LSTRA
Colon 38	Hepatoma 129	Mecca
	Hepatoma 134	NK
		6C3HED
<u>Ependymoblastoma</u>	<u>Inguinal</u>	<u>Mammary</u>
Ependymoblastoma	Krebs Ascites	Adenocarcinoma 755
	Krebs-2	BW10232 (Jax)
<u>Fibrosarcoma</u>		CE1460 MACA
36257 TTT	<u>Leukemias</u>	CH
Hepatoma 129	C58/J Spont.	C3HBA (Jax)
	C1498	DBA/2 Spont. M114
38290 TTT	Egg/Mouse	Ehrlich Ascites
Hepatoma 134	E Male/Gross	EMT-6
	Gross	Gross
46362 TTT	L1210	H2712 (Jax)
	L4946	Klein
46363 TTT	L5178Y	MA13C
	P288	MA16C
FB SAR	P388	MC- <u>n</u>
SaD2 (Jax)	P815	MCS-1
	P1534	MXT
	P1798	Spont. DBA/2
	RBL- <u>n</u>	

ADDENDUM A (continued)

<u>Melanoma</u>	<u>Pituitary</u>	<u>Sarcoma</u>
B16	A+T	Lewis
Harding-Passey	BW8685 (Jax)	MA387
HP (Jax)	BW8883 (Jax)	METH-A
<u>Nervous System</u>	T+T #15	MS-2
	T+T #97	S37
		S180
C1300 (Jax)	<u>Plasmacytoma</u>	Sa-1 (Jax)
Ependymoblastoma		
Glioma	ADJ-PC-n	<u>Squamous</u>
	LPC-1	
<u>Osteogenic</u>	MOPC-n	LC-12
	MPC-n	
HE10734	RPC-n	<u>Testicular</u>
	YPC-1	
<u>Pancreas</u>	70429	M5480
PAN 02	<u>Reticulum Cell</u>	<u>Teratosarcoma</u>
PAN 03		
	Friend Virus Leukemia	LS402AX
	M5076	
	SJL/JW	<u>Thymus</u>
	91632	
		Reif-Allen

*Refer to Inventory for details. A designation followed by n, e.g., MOPC-n, indicates that there is a series of tumors with this main designation, e.g., MOPC-4, MOPC-17, MOPC-21, etc.

ADDENDUM B

MOUSE TUMORS LISTED BY HOST STRAIN*

INBRED HOSTS

<u>A/HE</u>	<u>BALB/c (cont'd)</u>	<u>C57BL/6 (cont'd)</u>
C4461 Hauschka Ascites Klein (TA3)	RPC- <u>n</u> S37 YPC-1 1247	C1498 Colon 38 EL-4 E Male Gross
<u>A/J</u>	36257 TTT 38290 TTT 42021 TCT 44316 TST 44316 LTST 44347 TST 46363 TTT	Ependymoblastoma FCB Glioma 26 Glioma 261 L18464 Lewis Lung Lewis Sarcoma T241 LS402AX M5076 M5480 NK-Lymphoma PAN 02 PAN 03 RBL- <u>n</u> T+T #15
C1300 (Jax) H6 (Jax) Sa 1 (Jax)		42022 TST 42052 TST 42076 TST 46362 TTT 91632
<u>AKR</u>	<u>CE</u> CE1460 MACA	<u>C57L/J</u> BW7756 (Jax) BW8883 (Jax)
L4946 MA387 Mecca Reif-Allen	<u>C3H</u> C3HBA (Jax) FB SAR Gross Leukemia H2712 (Jax) HE 10734 Hepatoma 129 Hepatoma 134 J30237 Krebs Ascites Carcinoma Krebs 2 Carcinoma MA13C MA16C Mecca X5563 6C3HED 70429	<u>C57BR/cdj</u> BW8685 (Jax)
<u>BALB/c</u>		<u>C58</u> C58J/Spont.
ADJ-PC- <u>n</u> ASB XIV CA07/A CA36/Ara C CA51 Colon 26 EMT-6 Harding-Passey HP (Jax) LC-12 LPC-1 LSTRA M4898 Madison Lung MC- <u>n</u> METH-A Moloney Sarcoma MOPC- <u>n</u> MPC- <u>n</u> MS-1 MS-2 P1798	<u>C57BL/6</u> Adenocarcinoma 755 B16 BL12 BW 10232 (Jax)	

ADDENDUM B (continued)

<u>DBA/1</u>	<u>DBA/2 (cont'd)</u>	<u>DBA/2 (cont'd)</u>
CaD1 (Jax)	Gross Mammary	Spont. DBA/2 Mammary
dbrB (Jax)	Adenocarcinoma	T1699 (Jax)
S37 (Jax)	L1210	
S91 (Jax)	L5178Y	<u>SJL/J</u>
T1703 (Jax)	Nettesheim	SJL/JW
	P288	
<u>DBA/2</u>	P329	<u>129</u>
	P388	
CAD2	P815	LS402AX
DBA/2 Spont. M114	P1534	
Egg/Mouse Leukemia	S180	
Friend Virus Leukemia	SaD2 (Jax)	

F₁ HYBRIDS AND NON-INBRED HOSTS

<u>Swiss</u>	<u>LAF₁</u>	<u>CDF₁</u>
Ehrlich Ascites	AT	R- <u>n</u>
S180	LAF ₁	RC-2
	MST	102A
<u>BDF₁</u>	T+T #97	
MXT	<u>CAF₁</u>	Various resistant lines of L1210 and P388
Various resistant lines of L1210 and P388	Lymphoma-2	

*Refer to Inventory for details. A designation followed by n, e.g., MOPC-n, indicates that there is a series of tumors with this main designation, e.g., MOPC-4, MOPC-17, MOPC-21, etc.

ADDENDUM C

DRUG-RESISTANT MURINE LEUKEMIAS AND TREATMENT INFORMATION*

L1210 Lymphoid Leukemia

L1210/TSC (NSC-729)	L1210/Ara-C (NSC-63878)
L1210/MTX (NSC-740)	L1210/cis-DDP (NSC-119875)
L1210/6MP (NSC-755)	L1210/Anhydro Ara C (NSC-145668)
L1210/L-PAM (NSC-8806)	L1210/Ftorafur (NSC-148958)
L1210/NSC-19622	L1210/L-Alanosine (NSC-153353)
L1210/5FU (NSC-19893)	Note: Reo3 ⁺
L1210/CTX (NSC-26271)	L1210/BCNU (NSC-409962)
L1210/DF8 (NSC-29630)	L1210/C95 (NSC-740, 755, 26271)
L1210/HU (NSC-32065)	L1210/FR3 DCM/R 100a
L1210/MeGAG (NSC-32946)	L1210/FR8/DCM
L1210/NSC-38280	L1210/RT8 (Folate Reductase)
L1210/DTIC (45388)	L1210/M-773
L1210/TIC (NSC-60339)	L1210/6MP/6TG

*Treatment information, where available, is given in the following pages. When resistant lines are shipped, treatment information, if any, is included.

P388 Lymphocytic Leukemia

P388/MTX (NSC-740)	P388/L-Alanosine (NSC-153353)
P388/Actinomycin D (NSC-3053)	P388/Acivicin (NSC-163501)
P388/DON (NSC-7365)	P388/Amsacrine (NSC-249992)
P388/L-PAM (NSC-8806)	P388/Anthracenedione (NSC-287513)
P388/5-FU (NSC-19893)	Note: Reo3 ⁺
P388/CPA (NSC-26271)	P388/Mitoxantrone (NSC-299195 + 301739)
P388/Ara C (NSC-63878)	P388/Ara-A + 2'dcF (NSC-404241 + 218321)
P388/Daunomycin (NSC-82151)	P388/BCNU (NSC-409962)
P388/5-Azacytidine (NSC-102816)	
P388/DDP (NSC-119875) Note: Reo3 ⁺	
P388/ADR (NSC-123127)	

Other Resistant Leukemias

L5178/L-Ase R
P288/MTX (NSC-740)
P815/VLB (NSC-49842)

DRUG-RESISTANT MURINE LEUKEMIAS - TREATMENT INFORMATION FOR LINES RECEIVED
FROM SOUTHERN RESEARCH INSTITUTE AND ARTHUR D. LITTLE, INC.

Tumor Line	Host of Origin, Resistant Line	Passage Inoculum (i.p.)	Treatment Used with Serial Passage			Optimal Treatment to Check Degree of Resistance				
			NSC #	mg/Kg	Route	Schedule	NSC #	mg/Kg	Route	Schedule
L1210/TSC (NSC-729)	DBA/2 or CDF1	10 ⁵	729	5.0	i.p.	Days 1-6	729	6.0	i.p.	Q3Hx8 Days 1,5,9
L1210/6-MP (NSC-755)	DBA/2	10 ⁶	NONE				755	50.0	i.p.	QD1-9 days
L1210/L-PAM (NSC-8806)	BDF1	10 ⁶	8806	7.5	i.p.	Day 2 only	8806	15.0	i.p.	Day 1 only
L1210/CPA (NSC-26271)	DBA/2	10 ⁵	NONE				26271	265.0	i.p.	Day 1 only
L1210/HU (NSC-32065)	DBA/2 or CDF1	10 ⁵	32065	130.0	i.p.	Days 1-6	32065	60.0	i.p.	Q3Hx8 Days 1,5,9
L1210/ARA-C (NSC-63878)	DBA/2 or hybrid	10 ⁵	NONE				135962	125.0	i.p.	Day 1 only
L1210/DDP (NSC-119875)	DBA/2 or CDF1	10 ⁶	119875	5.0	i.p.	Day 4 only	119875	8.0	i.p.	Day 1 only
L1210/BCNU (NSC-409962)	BDF1	10 ⁵	NONE				409962	30.0	i.p.	Day 1 only
P388/MTX (NSC-740)	DBA/2 or CDF1	10 ⁷	740	0.75	s.c.	Days 1-6	740	2.0	i.p.	QD1-9 days
P388/ACT-D (NSC-3053)	DBA/2 or CDF1	10 ⁷	3053	0.2	i.p.	Day 4 only	3053	0.5	i.p.	Day 1 only
P388/L-PAM (NSC-8806)	BDF1	10 ⁶	8806	7.5	i.p.	Day 2 only	8806	15.0	i.p.	Day 1 only
P388/5-FU (NSC-19893)	BDF1	10 ⁷	19893	20.0	s.c.	Days 1-6	19893	25.0	i.p.	QD1-9 days
P388/CPA (NSC-26271)	BDF1	10 ⁷	26271	100.0	s.c.	Day 4 only	26271	265.0	i.p.	Day 1 only
P388/VCR (NSC-67574)	BDF1	10 ⁷	NONE				67574	1.5	i.p.	Days 1,5,9

Tumor Line	Host of Origin, Resistant Line	Passage Inoculum (i.p.)	Treatment Used with Serial Passage			Optimal Treatment to Check Degree of Resistance				
			NSC #	mg/Kg	Route	Schedule	NSC #	mg/Kg	Route	Schedule
P388/AZACYT (NSC-102816)	DBA/2 or CDF1	10 ⁷	102816	40.0	i.p.	Day 4 only	102816	3.5	i.p.	QD1-9 days
P388/DDP (NSC-119875)	DBA/2 or CDF1	10 ⁷	119875	4.5	i.p.	Days 1&5	119875	5.3	i.p.	Days 1,5,9
P388/ADR (NSC-123127)	BDF1	10 ⁷	123127	6.0	i.p.	Day 2 only	123127	12.5	i.p.	Day 1 only
P388/ARA-A + 2'dCF (NSC-404241 + NSC-218321)	BDF1	10 ⁶	404241 + 218321	125.0 .02	i.p.	Days 2-4	404241 + 218321	60.0	i.p.	Q3Hx8, Days 1,5,9
								0.05		
						<u>OR</u>				
P388/BCNU (NSC-409962)	CDF1	10 ⁷	409962	25.0	i.p.	Day 2 only	409962	150.0	i.p.	QD1-9 days
								0.25		
								30.0	i.p.	Day 1 only

*NSC-218321 thirty minutes before NSC-404241 each time.

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Adenocarcinoma 755 (CA755, Bagg- Jackson, Adeno- carcinoma)	Mammary Adenocarcinoma	Solid, Ascites or Brei	C57BL	
ADJ-PC-6	Plasmacytoma	Solid or Ascites	BALB/c	
ASB XIV	Pulmonary Squamous Cell Carcinoma	Solid	BALB/c	MVM
AT (Clone Y ₁)	Adrenal	Solid	LAF ₁	
AtT/20	Anterior Pituitary	Solid	LAF ₁	
B16	Melanoma	Solid	C57BL/6	Also see Jax tumors
BL12 Sensitive	Lymphosarcoma	Solid	C57BL/Ka	
BL12/Hc Ra	Lymphosarcoma	Solid	C57BL/Ka	Resistant to cortisone
BW7756	Hepatoma	Solid	C57L/J	See Jax tumors
BW8685	Pituitary	Solid	C57BR/Cdj	See Jax tumors
BW8883	Pituitary	Solid	C57L/J	See Jax tumors
BW10232	Mammary Adenocarcinoma	Solid	C57BL/6J	See Jax tumors
C3HBA	Mammary Adenocarcinoma	Solid	C3H/An	See Jax tumors
C58/J Spontaneous	Leukemia	Spleen Brei	C58	
C95 Spleen/R				See L1210/C95
C1498	Myelogenous Leukemia	Solid	C57BL/6	
C4461	Lung Adenocarcinoma	Solid	A/He	
CA07/A	Colon Adenocarcinoma	Solid	BALB/c	
CA36/Ara C (NSC-63878)	Colon Adenocarcinoma	Solid	BALB/c	
CA51	Colon Adenocarcinoma	Solid	BALB/c	
CaD1	Mammary Adenocarcinoma	Solid	DBA/1J	See Jax tumors

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
CaD2	Mammary Adenocarcinoma	Solid	DBA/2	
CCO/1923	Hemangiosarcoma	Solid	B6C3F1	
CE1460 MACA	Mammary Adenocarcinoma	Solid	CE	
CH	Mammary Adenocarcinoma	Solid	Nude C3H	
Cloudman Melanoma	Melanoma	Solid	DBA/1J	See Jax S91
Colon 26	Carcinoma	Solid	BALB/c	
Colon 38	Carcinoma	Solid	C57BL/6	
Crocker Sarcoma				See S180
D ₁ T ₁₀				See LSTRA/DTIC
DBA/2 Spontaneous Tumor M114	Mammary Adenocarcinoma	Solid	DBA/2	
dbrB	Anaplastic Carcinoma	Solid	DBA/1J	See Jax tumors
Egg/Mouse Leukemia	Lymphocytic Leukemia	Ascites	DBA/2, Truslow Egg	
Ehrlich Ascites	Mammary Adenocarcinoma	Solid or Ascites	Various	Several lines
Ehrlich Ascites/6-TG (NSC-752)	Mammary Adenocarcinoma	Ascites	Swiss	Resistant to 6-Thioguanine
Ehrlich Ascites, Tetraploid	Mammary Adenocarcinoma	Ascites	Swiss	
EL-4 Male	Lymphoma	Solid, Spleen C57BL/6 Fragments & Ascites		
E Male Gross	Leukemia	Spleen Homogenate	C57BL/6	
EMT-6	Mammary Adenocarcinoma	Solid	BALB/c	
Ependyoblastoma (Zimmerman)	Ependyoblastoma	Solid	C57BL/6	
FB SAR (A)	Fibrosarcoma	Solid	C3H	
FB SAR (B)	Fibrosarcoma	Solid	C3H	
FCB (C)	Transitional Cell Carcinoma of Bladder	Solid	C57BL/6	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Friend Virus Leukemia (FV01)	Reticulum Cell Sarcoma	Solid or Spleen Homogenate	DBA/2	
Furth Tumor				See Carcinoma 1025
Glioma 26	Glioma	Solid	C57BL/6	
Glioma 261	Glioma	Solid	C57BL/6	
Gross Leukemia	Leukemia	Solid	C3H	
Gross Mammary Adenocarcinoma	Mammary Adenocarcinoma	Solid	DBA/2	
Hageman Mastocytoma				See P815
Harding-Passey	Melanoma	Solid	BALB/c	Melanotic and amelanotic types
Hauschka Ascites Tumor	Unknown	Ascites	A/He	
HE10734	Osteogenic Sarcoma	Solid	C3H	
HE10734/FR	Osteogenic Sarcoma	Solid	C3H	
Hepatoma 129 (HE129)	Hepatoma	Solid	C3H or Hybrid	
Hepatoma 134 (HE134, Shear Hepatoma 134)	Hepatoma	Ascites	C3H	
HP	Amelanotic Melanoma	Solid	BALB/cJ	See Jax tumors
H6	Hepatoma	Solid	A/J	See Jax tumors
H2712	Mammary Adenocarcinoma	Solid	C3H/HeJ	See Jax tumors
J-30237	Unknown	Ascites	C3H	
Klein Tumor (TA3)	Mammary Adenocarcinoma	Ascites	A/He or CAF ₁	Several lines
Krebs Ascites Carcinoma	Carcinoma of Inguinal Region	Ascites	C3H or CDBA	
Krebs 2 Carcinoma	Carcinoma of Inguinal Region	Ascites	C3H	
L1210	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	
L1210/TSC (NSC-729)	Lymphoid Leukemia	Ascites	DBA/2	Resistant to Thio-semicarbazone

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
L1210/MTX (NSC-740)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	Treated
L1210/6MP (NSC-755)	Lymphoid Leukemia	Ascites	DBA or Hybrid	Several lines
L1210/L-PAM (NSC-8806)	Lymphoid Leukemia	Ascites	DBA/2 or BDF ₁	Treated
L1210/NSC-19622	Lymphoid Leukemia	Ascites	DBA/2	
L1210/5FU (NSC-19893)	Lymphoid Leukemia	Ascites	BDF ₁	
L1210/CTX (NSC-26271)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	
L1210/DF8 (NSC-29630)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	Resistant to dichloromethotrexate
L1210/HU (NSC-32065)	Lymphoid Leukemia	Ascites	DBA/2	
L1210/MeGAG (NSC-32946)	Lymphoid Leukemia	Ascites or Spleen Homogenate	CDF ₁	
L1210/NSC-38280	Lymphoid Leukemia	Ascites	CDF ₁	
L1210/DTIC (NSC-45388)	Lymphoid Leukemia	Ascites or Solid	DBA/2 or CDBA	Untreated and treated lines
L1210/TIC (NSC-60339)	Lymphoid Leukemia	Spleen Homogenate	CDBA	Untreated and treated lines
L1210/Ara-C (NSC-63878)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or Hybrid	Untreated and treated lines
L1210/cis-DDP (NSC-119875)	Lymphoid Leukemia	Ascites	DBA/2	Treated
L1210/Anhydro-Ara C (NSC-145668)	Lymphoid Leukemia	Ascites	DBA/2 or Hybrid	Untreated and treated lines
L1210/Ftorafur (NSC-148958)	Lymphoid Leukemia	Ascites	DBA/2 or BDF ₁	Untreated and treated lines
L1210/BCNU (NSC-409962)	Lymphoid Leukemia	Ascites	DBA/2 or Hybrid	Untreated and treated lines
L1210/C95	Lymphoid Leukemia	Ascites or Spleen Homogenate	CDBA	CTX, MTX, MP resistant

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
L1210 FR3 DCM/R 100a	Lymphoid Leukemia	Spleen Homogenate	CDBA	
L1210/FR8/DCM	Lymphoid Leukemia	Spleen Homogenate	CDF ₁	
L1210/FR8 (Folate Reductase)	Lymphoid Leukemia	Spleen Homogenate	CDF ₁	
L1210/M-773	Lymphoid Leukemia	Ascites	DBA/2	Treated
L1210/6MP/6TG	Lymphoid Leukemia	Ascites	CDF ₁	Untreated and treated lines
L1210 variants				See PR ₁ C ₁ T5/ NSC-45388, PR ₁ SE ₁ T5 and PR ₁ SE ₁ T5/ NSC-45388
L4946	Lymphocytic Leukemia	Solid	AKR	
L5178Y	Leukemia	Ascites	DBA/2 or Hybrid	Several lines
L18464	Lymphoma	Solid	C57BL/6	
LAF ₁	Adrenal Cortical Adenocarcinoma	Solid	LAF ₁ /J	
LC-12	Pulmonary Squamous Cell Carcinoma	Solid	BALB/c	
Lewis Lung	Carcinoma	Solid	C57BL	
Lewis Lung/PALA (NSC-224131)	Carcinoma	Solid	C57BL/6	
Lewis Sarcoma T241	Pleiomorphic Cell Sarcoma	Solid	C57BL	
LPC-1	Plasmacytoma	Solid or Ascites	BALB/c	
LS402AX	Teratosarcoma	Solid	C57BL/6 and 129	
LSTRA	Lymphosarcoma	Ascites	BALB/c	Several lines
LSTRA/DTIC (NSC-45388)	Lymphosarcoma	Ascites	BALB/c	Untreated and treated lines
M4898	Lung Adenocarcinoma	Solid	BALB/c	
M5076	Reticulum Cell Sarcoma	Solid or Ascites	C57BL/6	
M5076/L-PAM (NSC-8806)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
M5076/HMM (NSC-13875)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated
M5076/cis-DDP (NSC-119875)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated
M5480	Testicular Carcinoma (Seminoma)	Solid	C57BL/6	
MA13C	Mammary Adenocarcinoma	Solid	C3H	
MA16C	Mammary Adenocarcinoma	Solid	C3H	
MA387	Fusiform Cell Sarcoma	Solid	AKR	
Madison Lung (TA109)	Carcinoma	Solid	BALB/c	
MC-5	Mammary Adenocarcinoma	Spleen	BALB/c	
MC-6 Female	Mammary Adenocarcinoma	Ascites	BALB/c	
MC-11	Mammary Adenocarcinoma	Spleen Homogenate	BALB/c	
MCS-1	Mammary Adenocarcinoma	Solid or Spleen Homogenate	BALB/c	
Mecca (ME61, MLS)	Lymphosarcoma	Solid or Ascites	C3H or AKR	
METH-A	Sarcoma	Ascites	BALB/c	
MLS				See Mecca
Moloney Sarcoma (SV-122-TR4)	Sarcoma	Solid	BALB/c	
MOPC-4	Plasmacytoma	Solid or Ascites	BALB/c	
MOPC-17	Plasmacytoma	Solid	BALB/c	
MOPC-21	Plasmacytoma	Solid or Ascites	BALB/c	
MOPC-28	Plasmacytoma	Solid	BALB/c	
MOPC-30	Plasmacytoma	Solid	BALB/c	
MOPC-31	Plasmacytoma	Solid	BALB/c	
MOPC-41	Plasmacytoma	Solid	BALB/c	
MOPC-46	Plasmacytoma	Solid	BALB/c	
MOPC-47	Plasmacytoma	Solid	BALB/c	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
MOPC-48	Plasmacytoma	Solid	BALB/c	
MOPC-49	Plasmacytoma	Solid	BALB/c	
MOPC-51	Plasmacytoma	Solid	BALB/c	
MOPC-61	Plasmacytoma	Solid	BALB/c	
MOPC-63	Plasmacytoma	Solid	BALB/c	
MOPC-67	Plasmacytoma	Solid	BALB/c	
MOPC-69	Plasmacytoma	Solid	BALB/c	
MOPC-70	Plasmacytoma	Solid	BALB/c	
MOPC-78	Plasmacytoma	Solid	BALB/c	
MOPC-88	Plasmacytoma	Solid	BALB/c	
MOPC-91	Plasmacytoma	Spleen Homogenate	BALB/c	
MOPC-96	Plasmacytoma	Solid	BALB/c	
MOPC-99	Plasmacytoma	Solid	BALB/c	
MOPC-104	Plasmacytoma	Solid	BALB/c	
MOPC-112	Plasmacytoma	Solid	BALB/c	
MOPC-113	Plasmacytoma	Solid	BALB/c	
MOPC-114	Plasmacytoma	Solid	BALB/c	
MOPC-116	Plasmacytoma	Solid	BALB/c	
MOPC-118	Plasmacytoma	Solid	BALB/c	
MOPC-121	Plasmacytoma	Solid	BALB/c	
MOPC-123	Plasmacytoma	Solid	BALB/c	
MOPC-129	Plasmacytoma	Solid	BALB/c	
MOPC-132	Plasmacytoma	Solid	BALB/c	
MOPC-140	Plasmacytoma	Solid	BALB/c	
MOPC-141	Plasmacytoma	Solid	BALB/c	
MOPC-157	Plasmacytoma	Solid	BALB/c	
MOPC-172	Plasmacytoma	Solid	BALB/c	
MOPC-173	Plasmacytoma	Solid	BALB/c	
MOPC-209	Plasmacytoma	Solid	BALB/c	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
MPC-1	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-2	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-15	Plasmacytoma	Solid	BALB/c	
MPC-25	Plasmacytoma	Solid	BALB/c	
MPC-26	Plasmacytoma	Solid	BALB/c	
MPC-31	Plasmacytoma	Solid	BALB/c	
MPC-36	Plasmacytoma	Solid	BALB/c	
MPC-37	Plasmacytoma	Solid	BALB/c	
MPC-40	Plasmacytoma	Solid	BALB/c	
MPC-42	Plasmacytoma	Solid	BALB/c	
MPC-44	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-48	Plasmacytoma	Solid	BALB/c	
MPC-49	Plasmacytoma	Solid	BALB/c	
MPC-59	Plasmacytoma	Solid	BALB/c	
MPC-60	Plasmacytoma	Solid	BALB/c	
MPC-63	Plasmacytoma	Solid	BALB/c	
MPC-64	Plasmacytoma	Solid	BALB/c	
MPC-67	Plasmacytoma	Solid	BALB/c	
MPC-73	Plasmacytoma	Solid	BALB/c	
MPC-H	Plasmacytoma	Solid	BALB/c	
MST	Mast Cell	Solid	LAF ₁	
MS-2	Sarcoma	Solid	BALB/c	
MXT	Mammary Ductal Papillary Carcinoma	Solid	BDF ₁	Estrogen Responsive
NK-Lymphoma	Lymphoma	Ascites	C57BL/6	
Nettesheim Lung (LePage Clone KLN205)	Squamous Cell Lung Carcinoma	Solid	DBA/2 or Hybrid	
P288	Lymphocytic Leukemia	Solid or Ascites	DBA/2 or CDBA	
P288/MTX (NSC-740)	Lymphocytic Leukemia	Ascites	DBA/2 or BDF ₁	
P388	Lymphocytic Leukemia	Ascites	DBA/2 or CDBA	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
P388/MTX (NSC-740)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/ActinomycinD (NSC-3053)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/DON (NSC-7365)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/L-PAM (NSC-8806)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P388/5FU (NSC-19893)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P388/CPA (NSC-26271)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P388/Ara-C (NSC-63878)	Lymphocytic Leukemia	Ascites	BDF ₁	
P388/VCR (NSC-67574)	Lymphocytic Leukemia	Ascites	BDF ₁	Untreated and treated lines
P388/Daunomycin (NSC-82151)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/5-Azacytidine (NSC-102816)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/ADR (NSC-123127)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P388/L-Alanosine (NSC-153353)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Acivicin (NSC-163501)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Amsacrine (NSC-249992)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Mitoxantrone (NSC-301739)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Ara-A + 2'dcF (NSC-404241 + NSC-218321)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P388/BCNU (NSC-409962)	Lymphocytic Leukemia	Ascites	BDF ₁	Treated
P815 (Hageman Mastocytoma)	Mast Cell Leukemia	Ascites	DBA/2 or Hybrid	
P815/VLB (NSC-49842)	Mast Cell Leukemia	Ascites	DBA/2 or BDF ₁	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
P1534	Lymphocytic Leukemia	Spleen Homogenate or Ascites	DBA/2	Several lines
P1798	Lymphosarcoma	Solid or Ascites	BALB/c	
P1798/CR-JS	Lymphoma	Solid	BALB/c	Glucocorticoid resistant, treated
P1798/CS-JS	Lymphoma	Solid	BALB/c	Glucocorticoid sensitive
PAN 02	Pancreas	Solid	C57BL/6	
PAN 03	Pancreas	Solid	C57BL/6	
PR ₁ C ₁ T5/NSC-45388	Lymphoid Leukemia	Ascites	CDF ₁	L1210 variant; treated
PR ₁ SE ₁ T5	Lymphoid Leukemia	Ascites	CDF ₁	L1210 variant
PR ₁ SE ₁ T5/NSC-45388	Lymphoid Leukemia	Ascites Homogenate	CDF ₁	L1210 variant; treated
R-26	Unknown	Ascites	CDF ₁	
R-46	Unknown	Ascites	CDF ₁	
R-53	Unknown	Ascites	CDF ₁	
R-74	Unknown	Ascites	CDF ₁	
RBL-5 (Rauscher Virus Induced Transplantable Tumor-5)	Leukemia	Ascites	C57BL/6	
RC-2	Renal Adenocarcinoma	Ascites	CDF ₁	
Reif-Allen Tumor	Thymoma	Ascites	AKR	
RPC-5	Plasmacytoma	Solid	BALB/c	
RPC-9	Plasmacytoma	Solid or Ascites	BALB/c	
RPC-20	Plasmacytoma	Solid or Ascites	BALB/c	
S37	Pleomorphic Cell Sarcoma	Ascites	BALB/c, Nonspecific	See Jax tumors
S180 (Crocker, S III)	Pleomorphic Cell Sarcoma	Solid or Ascites	BALB/c, Swiss or hybrids	See Jax tumors
Sa 1	Spindle Cell Sarcoma	Solid	A/J	See Jax tumors
Sa D2	Fibrosarcoma	Solid	DBA/2J	See Jax tumors
Shear Hepatoma 134				See Hepatoma 134

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
SJL/JW	Reticulum Cell Sarcoma	Spleen Homogenate	SJL/JW	
Spontaneous Adrenal	Adrenal	Solid	CE/J	
Spontaneous DBA/2 Mammary	Mammary Adenocarcinoma	Solid	DBA/2	
Spontaneous Mammary	Mammary Adenocarcinoma	Solid	DBA/2	
SV-122-TR4				See Moloney Sarcoma
TA3				See Klein tumor
TA109				See Madison Lung
T1699	Mammary Adenocarcinoma	Solid	DBA/2J	See Jax tumors
T1703	Mammary Adenocarcinoma	Solid	DBA/1J	See Jax tumors
X5563	Unknown	Solid	C3H/He	
YPC-1	Plasmacytoma	Ascites	BALB/c	
Zimmerman Ependymoblastoma				See Ependymoblastoma
6C3HED (Gardner)	Lymphosarcoma	Ascites	C3H	Several lines. See Jax tumors
6C3HED/AR Res.	Lymphosarcoma	Spleen Homogenate	C3H	
102A	Unknown	Ascites	CDF ₁	
1247	Mammary Adenocarcinoma	Solid	BALB/c	
36230 TLT	Hemangio-endothelioma	Solid	C57BL/6J	
36257 TTT	Fibrosarcoma	Solid	BALB/cAnN	
38290 TTT	Fibrosarcoma	Solid	BALB/cAnN	
42021 TCT	Hemangio-endothelioma	Solid	BALB/cAnN	
42022 TST	Hemangio-endothelioma	Solid	BALB/cAnN	
42052 TST	Hemangio-endothelioma	Solid	C57BL/6J	

SPECIES: MOUSE				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
42076 TST	Hemangio- endothelioma	Solid	C57BL/6J	
44316 TST	Hemangio- endothelioma	Solid	BALB/cAnN	
44316 LTST	Hemangio- endothelioma	Solid	BALB/cAnN	
44347 TST	Hemangio- endothelioma	Solid	BALB/cAnN	
46362 TTT	Fibrosarcoma	Solid	C57BL/6J	
46363 TTT	Fibrosarcoma	Solid	BALB/cAnN	
70429	Plasmacytoma	Ascites	C3H	
70429/Azaserine (NSC-3425)	Plasmacytoma	Ascites	C3HF/LW	
91632	Reticulum Cell Sarcoma	Solid	C57BL/Kaplan	

MOUSE TUMORS FROM
THE JACKSON LABORATORY

MOUSE TUMORS FROM THE JACKSON LABORATORY IN CRYOPRESERVATION IN THE DCTD TUMOR REPOSITORY

Tumor Designation	Tumor Type	Host Strain	Transplantation Frequency (days)	Host Survival (days)	Lag Time* (days)	Strain of Origin	Sex of Origin	MRI Bank #	MAP Test *
dbrB	Anaplastic Carcinoma	DBA/1J	7	7-9	5-7	DBA		J-730	LDH+
SaD2	Fibrosarcoma	DBA/2J	10	19-12	8-15	DBA/2J		J-765	LDH+
H6	Hepatoma	A/J	10-14	14-44	7-9	A/J		J-750	LDH+
BW7756	Hepatoma	C57L/J	14	13-31	12-16	C57L/J		J-748	LDH+
6C3HED (GL-1)	Lymphosarcoma	C3H/HeJ	7	7-9	16	C3h	--	J-744	LDH+
BW10232	Mammary Adenocarcinoma	C57BL/6J	10	23-30	11	C57BL/6J		J-762	LDH+
C3HBA	Mammary Adenocarcinoma	C3H/HeJ	10	39-77	11-16	C3H/An		H-758	LDH+
H2712	Mammary Adenocarcinoma	C3H/HeJ	7	14-27	11-19	C3H/HeHu		J-731	LDH+
CaD1	Mammary Adenocarcinoma	DBA/1J	10	25-43	9-17	DBA/1J		J-742	LDH+
T1703	Mammary Adenocarcinoma	DBA/1J	10	47-74	9-12	DBA/1Hu		J-737	LDH+
T1699	Mammary Adenocarcinoma	DBA/2J	10	19-39	8-10	DBA/2J		J-736	LDH+
HP	Melanoma (amelanotic)	BALB/cJ	14	28-77	19-23	nonlabred	--	J-746	LDH+
B16	Melanoma (amelanotic)	C57BL/6J	10	24-44	15-21	C57BL/6J	--	J-753	LDH+
S91	Melanoma (melanotic)	DBA/1J	17-21	49-98	16-18	DBA (Snell)	--	J-749	LDH+
C1498	Myeloid Leukemia	C57BL/6J	7	9-16	7-9	C57BL	--	J-738	LDH+
BW8883	Pituitary	C57L/J	60	182-273	65-73	C57L/J	--	J-756	LDH+

Tumor Designation	Tumor Type	Host Strain	Transplantation Frequency (days)	Host Survival (days)	Lag Time* (days)	Strain of Origin	Sex of Origin	MRI Bank #	MAP Test *
BW8685	Pituitary	C57BR/dcJ	90-120	210-238	395	C57BR/cdj		J-794	LDH+
S180	Pleomorphic Sarcoma	BALB/cJ	10	21-31	9-11	"white" mouse		J-757	LDH+
S37	Pleomorphic Sarcoma	DBA/1J	7	21-28	6-13	"stock" mouse		J-759	LDH+
C1300	Round cell (Neuroblastoma?)	A/J	10	19-32	14-21	A albino	--	J-734	LDH+ MHV+
Sal	Spindle-cell Sarcoma	A/J	7	9-15	7-9	A albino	--	J-733	LDH+

*Length of lag phase before measurable tumor growth (5 mm average diameter) is evident in the first passage post thaw.

*MAP Test - Murine Antigen Profile for 12 common viruses: PVH, Rco 3, Sendai, GDVII, K, Polyoma, MVH, MAB, MHV, LCM, Ectromelia, LDH. Only positive results are listed.

Adapted from Jax Notes, No. 424, December 1975.

RABBIT TUMORS

SPECIES: RABBIT				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Brown-Pearce	Carcinoma (Epithelioma)	Solid	New Zealand White or Dutch	
VX-2 (V2)	Skin Carcinoma	Solid	New Zealand White or Dutch	

RAT TUMORS

SPECIES: RAT				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
AA Ascites	Spontaneous Ascites	Ascites	Wistar	
ATC 64	Thyroid Carcinoma	Solid	Fischer 344	
9A Ascites	Spontaneous Ascites	Ascites	Inbred PA	
A546 (DMBZ Attenuated)	Unknown	Solid	Fischer 344	
A920 (Tetramin Attenuated Resistant)	Unknown	Solid	Fischer 344	
A1011	Unknown	Solid	Fischer 344	
A1131-AR	Unknown	Solid	Fischer 344	
A1138-AL	Unknown	Solid	Fischer 344	
A1140-CL-10	Unknown	Solid	Fischer 344	
BT/M520	Fibrosarcoma	Solid	Marshall 520	
Carcinosarcoma	Carcinosarcoma (skin) (18-day embryos)	Solid	Sprague-Dawley Derived Holtzman	
CA 20948	Pancreatic Acinar Carcinoma	Solid	Wistar	
CCO 1865	Mesothelioma	Solid	Fischer 344	
CSE	Fibrosarcoma	Solid	Fischer 344	H-1
DD81-23	T cell lymphoma	Mince	Fischer 344	
DL Wells-17	T cell lymphoma	Mince	Fischer 344	
DMBA	Mammary Adenocarcinoma	Solid	Fischer 344	Several lines
DSL62-38	Pancreatic Tumor	Solid	Wistar Lewis	
Dunning Leukemia	Atypical Monocytic Leukemia	Solid or Ascites	Fischer 344	H-1 H-1, KRV
Dunning Leukemia/ NSC-755 (6-MP)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-3088 (chlor-ambucil)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-10107 (nitromin)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-13875 (HMM)	Atypical Monocytic Leukemia	Solid	Fischer 344	

SPECIES: RAT				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Dunning Leukemia/ NSC-17261 (benzo- quinone)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-23892 (dimethyl- benzimidazole)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-26980 (mitomycin C)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-29422 (thio- guanosine)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-45059 (o-acetyl- tetramin)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-51845 (cyclo- hexylamine)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Flexner-Jobling	Seminal Vesicle Adenocarcinoma	Solid	Nonspecific, Sprague- Dawley or Wistar	
Fran Tumor	Ovarian Carcinoma	Ascites	Sprague-Dawley	
GBT/W	Glial Tumor	Solid	Wistar	
HB Lynch-Fibroma 522	Fibroma	Solid	Fischer 344	
Hepatoma NK				See Novikoff Hepatoma
HMC	Histiocytoma	Solid	Fischer 344	
H-372	Leydig	Solid	Fischer 344	
H-540	Leydig	Solid	Fischer 344	
Iglesias	Ovarian Carcinoma	Solid	ACI	
IRS 9802	Spindle Cell Sarcoma	Solid	Fischer 344	
LC-18	Hepatoma	Solid	Fischer 344	
Lymphoma 8	Lymphoma	Solid, Spleen Homogenate, Whole Blood	Lewis	
L.T.W. (Furth)	Leydig	Solid	Wistar	
MAMF2-TC	Fibrosarcoma	Solid	Fischer 344	
MET 149-2	Adenocarcinoma	Solid	Fischer 344	

SPECIES: RAT				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
Moore Sarcoma #1	Sarcoma	Solid	Wistar	
Morris Hepatomas	Hepatoma	Solid	Buffalo	
16	Hepatoma	Solid	Buffalo	
20	Hepatoma	Solid	Buffalo	
44	Hepatoma	Solid	Buffalo	
3924A	Hepatoma	Solid	ACI	
5123	Hepatoma	Solid	Buffalo	
7777	Hepatoma	Solid	Buffalo	
7800	Hepatoma	Solid	Buffalo	
8999	Hepatoma	Solid	Buffalo	
9618A	Hepatoma	Solid	Buffalo	
MNU-Buffalo	Mammary Carcinoma	Solid	Buffalo	Several lines
MtT	Anterior Pituitary	Solid	Fischer, Wistar	Several lines
MT/W9	Mammary Adenocarcinoma	Solid	Wistar	Several lines
MT/W449	Mammary Adenocarcinoma	Solid	Wistar	Several lines
Murphy-Sturm Lymphosarcoma (MSL)	Lymphosarcoma	Solid	CRL, Wistar, Fischer 344, Sprague-Dawley	
NBW-37	T cell lymphoma	Mince	Fischer 344	
Novikoff Hepatoma (Hepatoma NK)	Hepatoma	Solid or Ascites	Random bred albino (Sprague-Dawley weanlings)	
NS104	Rhabdomyosarcoma	Solid	Fischer 344	
OR-16-3	Thymus Tumor	Solid	Fischer 344	
R35	Mammary Adenocarcinoma	Solid	Holtzman	
R3259	Giant Cell Sarcoma	Solid	Fischer 344	
Rice D6	Leydig	Solid	Fischer 344	
Rice 500	Leydig	Solid	Fischer 344	
Riejoel	Thyroid Adenocarcinoma	Solid	Fischer 344	
RNC 259	Pheochromocytoma	Solid	NEDH	

SPECIES: RAT				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
RNC 288	Insulinoma	Solid	NEDH	
RNK-16	LGL Leukemia	Solid or Spleen Homogenate	Fischer 344	
R3149	Leukemia	Solid	Fischer 344	
R3230AC	Mammary Adenocarcinoma	Solid	Fischer 344	
R3327	Prostate	Solid	Copenhagen 2331	
R3327 (Pap)	Prostate	Solid	Copenhagen 2331	
3M2N	Mammary Squamous Cell Carcinoma	Solid	Fischer 344	
Shay Leukemia	Myelogenous Leukemia	Solid	Sprague-Dawley	
SMT-2A	Mammary Carcinoma	Solid	Fischer 344	
Swarm	Chondrosarcoma	Solid	Sprague-Dawley	
TR.CLXXXVIII	Melanoma	Solid	ACI	
TR.DCCXLIII	Pituitary	Solid	ACI	
Walker 256	Carcinosarcoma	Solid or Ascites	Sprague-Dawley	
Yoshida Hepatoma	Hepatoma	Ascites	Sprague-Dawley	
Yoshida Sarcoma	Sarcoma	Solid or Ascites	Holtzman, S-D	
68-2	Alveolar/Bronchiolar Carcinoma	Solid	Fischer 344	
13762	Mammary	Solid or Ascites	Fischer 344	Several lines
13762-FS	Fibrosarcoma	Solid	Fischer 344	
23 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
29 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
33 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
2982	Olfactory Neuroblastoma	Solid	Fischer 344	
11095	Prostate	Solid	Fischer 344	

RAT TUMORS FROM DR. ROBERT NOBLE
(ENDOCRINE-RESPONSIVE)

SPECIES: RAT (tumors received from Dr. Robert Noble)

Information concerning the endocrinologic characteristics of the various tumor systems indicated in the "comments" is that supplied by Dr. Noble.

SPECIES: RAT (tumors received from Dr. Robert Noble)				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
1 Cvx-34A(1)	Cervical Carcinoma	Solid	NB	
1 Cvx-44Z	Cervical Carcinoma	Solid	NB	Estrogen dependent
1 Lym-206	Lymphoma	Solid	NB	Hormone stimulated
1 Lym-209(A)	Lymphoma	Solid	NB	Hormone stimulated, VLB sensitive
1 Lym-214	Lymphosarcoma	Solid	NB	Hormone stimulated
1 Og-3	Osteogenic Sarcoma	Solid	NB	
1 Pan-14Ax(1)	Adenocarcinoma	Solid	NB	Hormone stimulated
1 Sal-23(2)	Salivary Gland, Secretory Tumor	Solid	NB	Estrogen dependent
1 Tes-13E	Leydig Cell Carcinoma	Solid	NB	Estrogen dependent
1 TES-15E	Leydig Cell Carcinoma	Solid	NB	Estrogen dependent
Kid-27B	Kidney Adenocarcinoma	Solid	NB	
2 Lym-11(a)	Metaplastic, Adeno- carcinoma Fibroblast Overgrowth	Solid	NB	Estrogen dependent
2-Pan-6A	Pituitary Adenoma	Solid	NB	Hormone stimulated
2-Pr-7A	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-9F	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-12	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-112Bx(1)	Prostatic Carcinoma, Scirrhous	Solid	NB	
2 Pr-114B	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-121D(1)	Prostatic Carcinoma, Secretory	Solid	NB	Androgen dependent
2 Pr-121D(1)/R	Prostatic Carcinoma	Solid	NB	Resistant to testosterone
2 Sk-103	Melanoma	Solid	NB	
2 Ut-10(5)	Fibroma	Solid	NB	Estrogen dependent
3 Kid-13	Kidney Adenocarcinoma	Solid	NB	

SPECIES: RAT (tumors received from Dr. Robert Noble)				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
3 Lym-19	Lymphosarcoma	Solid	NB	
4 Pan-6	Adenocarcinoma	Solid	NB	
4 Sk-3A(3)Z	Squamous Cell Carcinoma	Solid	NB	
4 Ut	Hemangiosarcoma	Solid	NB	
4 Ut-6(2)	Fibrosarcoma	Solid	NB	Estrogen dependent or hormone stimulated
5 Pan-7	Undifferentiated Pancreatic Carcinoma	Solid	NB	
5 Sal	Undifferentiated Carcinoma	Solid	NB	
5 Sk-3	Melanoma	Solid	NB	
5 Ut-2	Uterine Adenocarcinoma	Solid	NB	Estrogen dependent (?)
6 Pan-4	Undifferentiated Pancreatic Carcinoma	Solid	NB	
7 Ut-13	Endometrial Adenocarcinoma	Solid	NB	
8 Lym-9(1)	Lymphosarcoma	Solid	NB	VLB resistant
8 Lym-108(1)	Lymphatic Leukemia	Solid	NB	VLB resistant
9 Lym-23	Lymphosarcoma	Solid	NB	
10 Lym-4	Negative Spleen	Solid	NB	
11 Lym-9	Lymphosarcoma	Solid	NB	
13 Pr-5	Prostatic Carcinoma, Undifferentiated	Solid	NB	Estrogen pellet implant required
14 Lym-5	Lymphosarcoma stimulated	Solid	NB	Hormone
14 Pr-5	Prostatic Carcinoma	Solid	NB	
15 Pr-2	Prostatic Adenocarcinoma	Solid	NB	
16 Pr-3	Prostatic Adenocarcinoma	Solid	NB	
17 Lym-4	Lymphosarcoma implant required	Solid	NB	Estrogen pellet
17 Lym-5	Leukemia	Solid	NB	
18 Lym-6	Lymphosarcoma	Solid	NB	Estrogen dependent

SPECIES: RAT (tumors received from Dr. Robert Noble)				
Tumor Designation	Histologic Type	Form	Strain of Origin/ Transplant	Comments
19 Lym-3	Lymphosarcoma	Solid	NB	Estrogen dependent
19 Pr-19	Prostatic Fibroadenoma	Solid	NB	
20 Pr-1	Prostatic Fibroadenoma	Solid	NB	
20 Lym-3	Lymphosarcoma	Solid	NB	Estrogen pellet implant required
21 Pr-9	Prostatic Carcinoma	Solid	NB	
22 Pr-8	Prostatic Adenocarcinoma	Solid	NB	
23 Pr-7	Prostatic Carcinoma	Solid	NB	
24 Pr-2	Prostatic Carcinoma	Solid	NB	
25 Pr-3	Prostatic Adenocarcinoma	Solid	NB	

IN VITRO ESTABLISHED CELL LINES

HUMAN <i>IN VITRO</i> CELL LINES				
Designation	Tissue of Origin	Histologic Type	Growth Medium	Remarks
ACHN	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Schmid
A2780	Ovary	Adenocarcinoma	RPMI 1640	From Dr. Hamilton
A498	Kidney	Renal Cell Carcinoma	RPMI 1640	ATCC
A549	Lung	Non-small Cell	RPMI 1640	ATCC
A704	Kidney	Renal Cell Carcinoma	RPMI 1640	ATCC
BT-549	Breast	Adenocarcinoma	RPMI 1640	ATCC
CAKI-1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Loveless
CCRF-CEM	Lymph	Leukemia	RPMI 1640	ATCC
CCRF-SB	Lymph	Leukemia	RPMI 1640	ATCC
CHA-59	Bone	Osteosarcoma	RPMI 1640	From Drs. Shoemaker and McLachlan
COLO 205	Colon	Adenocarcinoma	RPMI 1640	ATCC
DMS-114	Lung	Small Cell	RPMI 1640	From Dr. Pettengill
DU-145	Prostate	Carcinoma	RPMI 1640	ATCC
EKVX	Lung	Adenocarcinoma	RPMI 1640	From Dr. Fodstad
HCC-2998	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
HCT-15	Colon	Carcinoma	RPMI 1640	ATCC
HCT-116	Colon	Adenocarcinoma	RPMI 1640	ATCC
HELA	Cervix	Carcinoma		
HOP-18	Lung	Large Cell Carcinoma	RPMI 1640	From Drs. Liu/Casero
HOP-62	Lung	Adenocarcinoma	RPMI 1640	From Drs. Liu/Casero
HOP-92	Lung	Large Cell	RPMI 1640	From Dr. Liu
HL-3		Lymphoma		
HL-4		Lymphoma		
HL-60	Ascites	Pro-myelocytic Leukemia	RPMI 1640	From E. Jensen
H-MESO-1		Mesothelioma	RPMI 1640	
HS 578T	Breast	Adenocarcinoma	RPMI 1640	ATCC
HS 913T	Lung	Mixed Cell	RPMI 1640	ATCC
HT-29	Colon	Adenocarcinoma	RPMI 1640	ATCC
IGR-OV1	Ovary	Adenocarcinoma	RPMI 1640	From Dr. Benard

HUMAN <i>IN VITRO</i> CELL LINES				
Designation	Tissue of Origin	Histologic Type	Growth Medium	Remarks
KB-ADL #12	Oral Cavity	Epidermoid	EMEM	
KM-12	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
KM 20L2	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
K-562	Lymph	Leukemia	RPMI 1640	ATCC
LOVO	Colon	Adenocarcinoma	RPMI 1640	ATCC
LOX IMVI	Lymph Node Metastasis	Amelanotic Melanoma	RPMI 1640	From Dr. Fodstad
LXFL 529**	Lung	Large Cell Carcinoma	RPMI 1640	From Dr. Fiebig**
MALME-3M	Lung Metastasis	Melanoma	RPMI 1640	ATCC
MCF7	Breast	Adenocarcinoma	RPMI 1640	From Dr. Cowan
MDA-MB-231	Breast	Adenocarcinoma	RPMI 1640	From Dr. Moore
MDA-MB-435	Breast	Adenocarcinoma	RPMI 1640	From Dr. Steeg
MOLT-4	Lymph	Leukemia	RPMI 1640	ATCC
MX-1	Breast	Carcinoma	RPMI 1640	From Dr. Giovannelli
M14		Amelanotic Melanoma	RPMI 1640	From Dr. Kern
M19-MEL		Amelanotic Melanoma	RPMI 1640	From Dr. Kern
NC-37	Lymphoblast	Normal		
NCI-H23	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar
NCI-H69	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H82	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H125	Lung	Adenosquamous Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H226	Lung	Squamous Cell	RPMI 1640	From Dr. Gazdar
NCI-H292	Lung	Adenosquamous Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H322M	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar
NCI-H358M	Lung	Bronchioalveolar Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H460	Lung	Large Cell	RPMI 1640	From Dr. Gazdar
NCI-H522	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar

HUMAN <i>IN VITRO</i> CELL LINES				
Designation	Tissue of Origin	Histologic Type	Growth Medium	Remarks
NCI/ADR-RES	Breast	Adenocarcinoma	RPMI 1640	From Dr. Cowan Please see JNCI correspondence on page 64
OV	Ovary			
OVCAR-3	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-4	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-5	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-8	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
PC-3	Prostate	Carcinoma	RPMI 1640	From Dr. Kaighn
PC-3/M	Prostate	Carcinoma	RPMI 1640	From Dr. Kaighn
RPMI-7951		Melanoma	RPMI 1640	ATCC
RPMI-8226	Lymph	Leukemia	RPMI 1640	ATCC
RXF 393**	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fiebig (DTP use only)
RXF 631**	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fiebig**
SF-268	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SF-295	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SF-539	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SHP-77	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Fisher
SK-OV-3	Ovary	Adenocarcinoma	RPMI 1640	ATCC
SK-MEL-2		Melanoma	RPMI 1640	ATCC
SK-MEL-5		Melanoma	RPMI 1640	ATCC
SK-MEL-28		Melanoma	RPMI 1640	ATCC
SK-MES-1	Lung	Squamous Cell Carcinoma	RPMI 1640	ATCC
SN12A1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12C	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12K1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12L1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12S1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SNB-7	CNS	Glioblastoma	RPMI 1640	From Dr. Kornblith
SNB-19	CNS	Glioblastoma	RPMI 1640	From Dr. Kornblith

HUMAN <i>IN VITRO</i> CELL LINES				
Designation	Tissue of Origin	Histologic Type	Growth Medium	Remarks
SNB-75	CNS	Glioblastoma	RPMI 1640	From Dr. Kornblith
SNB-78	CNS	Astrocytoma	RPMI 1640	From Dr. Kornblith
SR	Pleural effusion	Lymphoma	RPMI 1640	From Dr. Urba
SW-620	Colon		RPMI 1640	ATCC
T-47D	Breast		RPMI 1640	Not distributed to commercial firms or for commercial purposes
TK-10	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Clayman
UACC-62		Melanoma	RPMI 1640	From Dr. Leibowitz
UACC-257		Melanoma	RPMI 1640	From Dr. Leibowitz
UCSD 242L		Melanoma	RPMI 1640	From Dr. Taetle
UCSD 354L		Melanoma	RPMI 1640	From Dr. Taetle
UO-31	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Linehan
U-251	CNS	Glioblastoma	RPMI 1640	From Dr. Bigner
WIDR	Colon	Adenocarcinoma	RPMI 1640	ATCC
XF 498**	CNS	Glioblastoma	RPMI 1640	From Dr. Fiebig**
786-0	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Williams

**Requestor must obtain permission from the source BEFORE ordering. A copy of this permission must be submitted with the order.

Dr. Heiner Fiebig may be contacted at: Tumor Biology Center
at the University of Freiburg
Breisacher Str.117
79106 Freiburg, GERMANY
E: fiebig@uni-freiburg.de

NCI ANTI-CANCER CELL LINE PANEL						
Cell Line	Sex	Age	Histology	Comment	Treat-ment	Source
COLON						
COLO 205	M	70	Adenocarcinoma	Can Res 38: 1345-1355, 1978	Y	Ascites
HCC-2998			Carcinoma		N	
HCT-15			Adenocarcinoma	Can Res 39: 1020-1025, 1979		
HCT-116			Carcinoma	Can Res 41: 1761-1756, 1981		
HT29	F	44	Adenocarcinoma, GR III	Human Tumor Cells In Vitro: 115-159, 1975		Primary
KM12			Adenocarcinoma	Can Res 48: 1943-1948, 1988	N	
SW-60	M	51	Adenocarcinoma	Can Res 36: 4562-4569, 1976		Metastasis
CNS						
SF-268	F	24	Anaplastic Astrocytoma	Acta Neuropathol 75: 92-103, 1987		
SF-295	F	67	Glioblastoma-Multiforme	Acta Neuropathol 75: 92-103, 1987		
SF-539				J Neuropathol Exp Neurol 40: 201-229, 1981		
SNB-19	M	47	Glioma	Cancer 47: 255, 1981	N	
SNB-75	F		Astrocytoma		N	
U251	M	75	Glioblastoma	J Neuropathol Exp Neurol 40: 410-427, 1981		
LEUKEMIA						
CCRF-CEM	M	4	Acute Lymphoblastic Leukemia	Can Res 18: 522-529, 1965		
HL-60(TB)	F	36	Promyelocytic Leukemia	Nature 270: 347-349, 1977		PBL
K-562	F	53	Chronic Myelogenous Leukemia	Blood 45: 321-334, 1975		Pleural Effusion
MOLT-4	M	19	Acute Lymphoblastic Leukemia	JNCI 49: 891-895, 1972		PB
RPMI-8226	M	61	Myeloma	Proc Soc Exp Biol Med 125: 1246-1250, 1967		PB
SR	M	11	Large Cell, Immunoblastic		Y	
Lung						
A549/ATCC	M	58	Adenocarcinoma	JNCI 51: 1417-1423, 1973		Primary
EKVX	M		Adenocarcinoma			
HOP-62	F	60	Adenocarcinoma		N	
HOP-92	M	62	Large Cell, Undifferentiated		N	
NCI-H23			Adenocarcinoma	Can Res 45: 2913-2923, 1985	N	
NCI-H226			Squamous	Can Res 45: 2913-2923, 1985		

NCI ANTI-CANCER CELL LINE PANEL						
Cell Line	Sex	Age	Histology	Comment	Treat-ment	Source
LUNG (continued)						
NCI-H322M			Small Cell Bronchioalveolar Carcinoma		N	
NCI-H460	M		Large Cell Carcinoma	Science 246: 491-494, 1989	N	Pleural Effusion
NCI-H522			Adenocarcinoma	Can Res 45: 2913-2923, 1985		
MAMMARY						
MCF7	F	69	Adenocarcinoma	JNCI 51: 1409-1417, 1973	Y	
NCI/ADR-RES	F		Adenocarcinoma	JNCI 90(11): 6/3/1998		
HS 578T	F	74	Carcinosarcoma	JNCI 58: 1795-1806, 1977		Primary
MDA-MB-231	F	51	Adenocarcinoma	JNCI 53: 661-674, 1974	Y	
MDA-MB-435	F	31	Adenocarcinoma	Can Res 40: 3118-3129, 1980	N	
BT-549	F	72	Papillary Infiltrating Ductal Carcinoma	No Publication		Metastasis
T-47D*	F	54	Infiltrating Ductal Carcinoma	Eur J Cancer 15: 659-670, 1979		*not for commercial use
MELANOMA						
LOX IMVI			Malignant Amelanotic Melanoma	Int J Cancer 41: 442-449, 1988		
M14						
MALME-3M	M	43	Malignant Melanoma	Human Tumor Cells In Vitro, pp. 115-159, 1975		Metastasis
SK-MEL-2	M	60	Malignant Melanoma	Human Tumor Cells In Vitro, pp. 115-159, 1975		Metastasis
SK-MEL-5			Malignant Melanoma	PNAS 73: 3278-3282, 1976		Metastasis
SK-MEL-28			Malignant Melanoma	PNAS 73: 3278-3282, 1976		
UACC-62						
UACC-257						
OVARIAN						
IGR-OV1	F	47	Cystoadenocarcinoma	Can Res 45: 4970-4979, 1985	N	
OVCAR-3	F	60	Adenocarcinoma	Can Res 43: 5379-5389, 1983	Y	Ascites
OVCAR-4	F	42	Adenocarcinoma	Sem Oncol 11: 285-298, 1984	Y	
OVCAR-5	F	67	Adenocarcinoma	Sem Oncol 11: 285-298, 1984	N	
SK-OV-3	F	64	Adenocarcinoma	Human Tumor Cells In Vitro, pp. 115-159, 1975	Y	Ascites

NCI ANTI-CANCER CELL LINE PANEL						
Cell Line	Sex	Age	Histology	Comment	Treat-ment	Source
PROSTATE						
DU-145	M	69	Carcinoma	Int J Cancer 21: 274-281, 1978	Y	
PC-3	M	62	Adenocarcinoma	Invest Urol 17: 16-23, 1979	Y	Metastasis
RENAL						
786-O	M	58	Adenocarcinoma	In Vitro 12: 623-627, 1976	N	
A498	F	52	Adenocarcinoma	JNCI 51: 1417-1423, 1973		
ACHN	M	22	Renal Cell Carcinoma	Can Res 42: 4948-4953, 1982	Y	Pleural Effusion
CAK-1	M	49	Clear Cell Carcinoma	Human Tumor Cells In Vitro, pp. 115-159, 1975	Y	Metastasis
RXF 393*	M	54	Poorly Differentiated Hypernephroma	Contrib Oncol 42, 1992	N	*available only to DTP
SN12C	M	43	Carcinoma	Can Res 46: 4109-4115, 1986		
TK-10	M	43	Spindle Cell Carcinoma	Can Res 47: 3856-3862, 1987	N	
UO-31			Carcinoma		N	

CORRESPONDENCE

Cell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen

Since 1990, the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) has screened over 60,000 compounds and a larger number of natural product extracts for their capacity to inhibit the growth of 60 different human tumor cell lines (1). These cell lines have been maintained in cryopreservation and in culture, and they have been subjected to strict quality controls, including adventitious agent testing, human isoenzyme analysis, karyology, morphological and immunocytochemical characterization (2), and DNA fingerprinting. One of these cell lines, previously designated as MCF-7/ADR-RES, has been included in the *in vitro* cell line screening panel because of its stable multidrug-resistant (MDR) phenotype (3) characterized by high levels of MDR-1 and P-glycoprotein expression (4,5). Recently, we submitted cell lines from the screening panel for DNA fingerprinting analysis by three different laboratories. Included in the tested cell lines were MCF-7 and MCF-7/ADR-RES. Utilizing restriction fragment length polymorphism (RFLP) testing, CellMark Diagnostics (Germantown, MD) concluded that their DNA fingerprinting data were consistent with each of the cell lines (MCF-7 and MCF-7/ADR-RES) having different donors. The other laboratories—American Type Culture Collection (Rockville, MD) used both RFLP and amplification fragment length polymorphism (AmpFLP) methods, and Children's Hospital of Michigan Cell Culture Laboratory (Detroit, MI) used the AmpFLP method—reached the same conclusions. Based on the reports from these DNA fingerprinting analyses, we have concluded that the preponderance of the information available suggests that the MCF-7/ADR-RES multidrug-resistant cell line that is included in the DTP screening program is not related to the MCF-7 cell line that is a part of the screening panel. **Thus, we have changed the nomenclature of the MCF-7/ADR-RES multidrug-resistant cell line.** The new designation of this cell line is **NCI/ADR-RES**. This nomenclature change will soon appear in all DTP databases, including the Worldwide Web. The DTP Web site address is: <http://dtp.nci.nih.gov>

Irrespective of its origin, this cell line has served as a valuable sentinel for compounds interacting with the multidrug-resistant mechanism (5).

DOMINIC A. SCUDIERO
ANNE MONKS
EDWARD A. SAUSVILLE

References

- (1) Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst* 1991; 83:757-66.
- (2) Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-orientated anticancer drug screen. *Anticancer Res* 1992; 12:1035-53.
- (3) Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, et al. Multidrug-resistant phenotype of disease-orientated panels of human tumor cell lines used for anticancer drug screening. *Cancer Res* 1992;52:3029-34.
- (4) Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. *Mol Pharmacol* 1994; 46:627-38.
- (5) Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. *J Clin Invest* 1995; 95:2205-14.

Notes

Affiliations of authors: D. A. Scudiero, A. Monks, Science Applications International Corp., National Cancer Institute at Frederick, Frederick, MD; E. A. Sausville, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, and Centers, National Cancer Institute, Bethesda, MD.

Correspondence to: Dominic A. Scudiero, Ph.D., Science Applications International Corp., National Cancer Institute at Frederick, Box B, Bldg. 432, Frederick, MD 21702-1201.

NONHUMAN <i>IN VITRO</i> CELL LINES					
Designation	Species	Histologic Type	Tissue of Origin	Growth Medium	Remarks
CHO 1C T6	Hamster	Normal	Ovary	F12	
B16F ₁	Mouse	Melanoma	Ear (B16)	EMEM	From Fidler
B16F ₁₀	Mouse	Melanoma	Lung met.	EMEM	From Fidler; high lung met.
B16F ^{Lr6}	Mouse	Melanoma	Lung met.	EMEM	From Fidler; low lung met.
B16BL-6	Mouse	Melanoma	Bladder met.	EMEM	From Fidler; intermediate lung met.
BALB/c 3T3	Mouse	Normal	Embryo	Dulbecco	
C3HIOT 1/2	Mouse				No info
Colon 26	Mouse	Carcinoma	Colon	RPMI 1640	
EL-4	Mouse	Lymphoma			
FBL-3	Mouse	Leukemia			
Lewis Lung	Mouse	Carcinoma	Lung	EMEM	
L1210/MRI	Mouse	Leukemia	Ascites	Fischer's	
L5178Y(R)/MRI	Mouse	Leukemia	Ascites	Fischer's	
MPC-11	Mouse	Myeloma			
M5076	Mouse	Reticulum cell sarcoma		RPMI 1640	
P3X63	Mouse				No info
P388	Mouse	Leukemia	Ascites	RPMI 1640	
P388/ADR	Mouse	Leukemia	Ascites	RPMI 1640	
PAN 02	Mouse	Adenocarcinoma	Pancreas	RPMI 1640	
YAC	Mouse	Lymphoma		EMEM	
K-1735	Mouse	Melanoma		EMEM	
UV-2237	Mouse	Fibrosarcoma		EMEM	
MADB 106	Rat				
MADB 200	Rat				

YEAST STRAINS

YEAST STRAINS USED FOR NCI COMPOUND SCREENING		
SPY #	Relevant Mutation(s)	Complete Genotype
50636	<i>rad52</i>	<i>MATα rad52ΔURA3 erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50644	none (wild-type control)	<i>MATα erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50648	<i>rad50</i>	<i>MATα rad50Δkan' ade2 ade3 leu2 ura3 trp1 cyh2</i>
50649	<i>mlh1 rad18</i>	<i>MATα mlh1ΔTRP1 rad18ΔLEU2 erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2 (trp1?)</i>
50650	<i>mgt1</i>	<i>MAT mtg1Δkan' erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50652	<i>rad50</i>	<i>MATα rad50Δkan' erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50654	<i>mec2-1</i>	<i>MATα mec2-1 erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50740	<i>rad14</i>	<i>MATα rad14Δkan' erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50745	<i>sgs1 mgt1</i>	<i>MATα sgs1ΔLEU2 mgt1kan' erg6ΔLEU2 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 ura3 cyh2</i>
50768	<i>GPDp-CLN2</i>	<i>MATα URA3-GPDp-CLN2 erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50771	<i>GPDp-CLN2 rad14</i>	<i>MATα URA3-GPDp-CLN2 rad14Δkan' erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 ura3 cyh2 trp1</i>
50779	<i>bub3</i>	<i>MATα bub3ΔURA3 erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 ura3 cyh2 trp1</i>
50780	none (wild-type control)	<i>MATα erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50834	<i>mlh1</i>	<i>MATα mlh1ΔTRP1 erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 ura3 cyh2</i>
50835	<i>sgs1</i>	<i>MATα sgs1ΔLEU2 erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 ura3 cyh2</i>
50891	<i>rad18</i>	<i>MATα rad18ΔURA3 erg6ΔTRP1 pdr1ΔLEU2 pdr3ΔhisG ade2 ade3 leu2 trp1 ura3 cyh2</i>

Notes:

- 1) Store at -70°C to -80°C. To establish working stock: scrape frozen culture with a wooden applicator stick and apply sample to agar-containing media (vials should remain frozen).
- 2) All strains are derived from L. Hartwell laboratory strains in the A364a genetic background.
- 3) The *erg6 pdr1 pdr3* mutations in all strains serve to make yeast more sensitive to a variety of compounds.
- 4) The allele present at the *TRP1* locus is unknown for SPY50649 (strain is phenotypically Trp⁺ by virtue of *TRP1* at the *MLH1* locus).

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
16 Morris	Hepatoma	Rat	50
20 Morris	Hepatoma	Rat	50
44 Morris	Hepatoma	Rat	50
786-0	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	60
1247	Mammary Adenocarcinoma	Mouse	40
2982	Olfactory Neuroblastoma	Rat	51
4671	Pancreatic Duct Adenocarcinoma	Hamster	19
5123 Morris	Morris Hepatoma	Rat	50
7777 Morris	Morris Hepatoma	Rat	50
7800 Morris	Morris Hepatoma	Rat	50
8999 Morris	Morris Hepatoma	Rat	50
9618A Morris	Hepatoma	Rat	50
9242	Parotid Acinar Cell Adenocarcinoma	Hamster	19
10838	Seminoma	Hamster	19
11095	Prostate	Rat	51
13762	Mammary	Rat	52
22047	Adenocarcinoma	Hamster	19
50636		Yeast Strains	67
50644		Yeast Strains	67
50648		Yeast Strains	67
50649		Yeast Strains	67
50650		Yeast Strains	67
50652		Yeast Strains	67
50654		Yeast Strains	67
50740		Yeast Strains	67
50745		Yeast Strains	67
50768		Yeast Strains	67
50771		Yeast Strains	67
50779		Yeast Strains	67
50780		Yeast Strains	67
50834		Yeast Strains	67
50835		Yeast Strains	67
50891		Yeast Strains	67
70429	Plasmacytoma	Mouse	41
91632	Reticulum Cell Sarcoma	Mouse	41
LC-18	Hepatoma	Rat	49
10-24	Mesothelioma	Hamster	19
102A	Unknown	Mouse	40
11348P	Pulmonary Squamous Cell Carcinoma	Hamster	19
11963V	Leiomyosarcoma	Hamster	19
13762-FS	Fibrosarcoma	Rat	51
1382J	Liver Carcinoma	Hamster	19
1 Cvx-34A(1)	Cervical Carcinoma	Rat	53
1 Cvx-44Z	Cervical Carcinoma	Rat	53
1 Lym-206	Lymphoma	Rat	53

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
1 Lym-209 (A)	Lymphoma	Rat	53
1 Lym-214	Lymphosarcoma	Rat	53
1 Og-3	Osteogenic Sarcoma	Rat	53
1 Pan-14Ax(1)	Adenocarcinoma	Rat	53
1 Sal-23(2)	Salivary Gland, Secretory Tumor	Rat	53
1 Tes-13E	Leydig Cell Carcinoma	Rat	53
1 TES-15E	Leydig Cell Carcinoma	Rat	53
2 Lym-11(a)	Metaplastic, Adenocarcinoma Fibroblast Overgrowth	Rat	53
23 Methapyrilene	Hepatocellular Carcinoma	Rat	51
2309V	Pancreatic Islet Cell Adenocarcinoma	Hamster	19
29 Methapyrilene	Hepatocellular Carcinoma	Rat	51
2-Pan-6A	Pituitary Adenoma	Rat	53
2-Pr-7A	Prostatic Adenocarcinoma	Rat	53
2 Pr-9F	Prostatic Adenocarcinoma	Rat	53
2 Pr-12	Prostatic Adenocarcinoma	Rat	53
2 Pr-112Bx(1)	Prostatic Carcinoma Scirrhus	Rat	53
2 Pr-114B	Prostatic Adenocarcinoma	Rat	53
2 Pr-121D(1)	Prostatic Carcinoma, Secretory	Rat	53
2 Pr-121D(1)R	Prostatic Carcinoma, Secretory	Rat	53
2 Sk-103	Melanoma	Rat	53
2 Ut-10(5)	Fibroma	Rat	53
3 Lym-19	Lymphosarcoma	Rat	54
33 Methapyrilene	Hepatocellular Carcinoma	Rat	51
36230 TLT	Hemangioendothelioma	Mouse	40
36257 TTT	Fibrosarcoma	Mouse	40
38290 TTT	Fibrosarcoma	Mouse	40
3924A	Hepatoma	Rat	50
3M2N	Mammary Squamous Cell Carcinoma	Rat	51
4 Pan-6	Adenocarcinoma	Rat	54
4 Sk-3A(3)Z	Squamous Cell Carcinoma	Rat	54
4 Ut	Hemaniosarcoma	Rat	54
4 Ut-6(2)	Fibrosarcoma	Rat	54
42021 TCT	Hemangioendothelioma	Mouse	40
42022 TST	Hemangioendothelioma	Mouse	40
42052 TST	Hemangioendothelioma	Mouse	40
42076 TST	Hemangioendothelioma	Mouse	40
44316 LTST	Hemangioendothelioma	Mouse	40
44316 TST	Hemangioendothelioma	Mouse	40
44347 TST	Hemangioendothelioma	Mouse	40
46362 TTT	Fibrosarcoma	Mouse	40
46363 TTT	Fibrosarcoma	Mouse	41
5 Pan-7	Undifferentiated Pancreatic Carcinoma	Rat	54
5 Sal	Undifferentiated Carcinoma	Rat	54
5 Sk-3	Melanoma	Rat	54
5 Ut-2	Uterine Adenocarcinoma	Rat	54

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
68-2	Alveolar/Bronchiolar Carcinoma	Rat	51
6973P	Leiomyosarcoma	Hamster	19
6C3HED	Lymphosarcoma	Jackson Lab Mouse	43
6C3HED (Gardner)	Lymphosarcoma	Mouse	40
6C3HED/AR Res.	Lymphosarcoma	Mouse	40
6 Pan-4	Undifferentiated Pancreatic Carcinoma	Rat	54
70429/Azaserine (NSC-3425)	Plasmacytoma	Mouse	41
786-0	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	60
7 Ut-13	Endometrial Adenocarcinoma	Rat	54
8721R	Renal Carcinoma	Hamster	19
8746Q	Uterine Adenocarcinoma	Hamster	19
8 Lym-9(1)	Lymphosarcoma	Rat	54
8 Lym-108(1)	Lymphatic Leukemia	Rat	54
9618A	Hepatoma	Rat	50
9A Ascites	Spontaneous Ascites	Rat	48
9 Lym-23	Lymphosarcoma	Rat	54
10 Lym-4	Negative Spleen	Rat	54
11 Lym-9	Lymphosarcoma	Rat	54
13 Pr-5	Prostatic Carcinoma, Undifferentiated	Rat	54
14 Lym-5	Lymphosarcoma Stimulated	Rat	54
14 Pr-5	Prostatic Carcinoma	Rat	54
15 Pr-2	Prostatic Adenocarcinoma	Rat	54
16 Pr-3	Prostatic Adenocarcinoma	Rat	54
17 Lym-4	Lymphosarcoma, implant required	Rat	54
17 Lym-5	Leukemia	Rat	54
18 Lym-6	Lymphosarcoma	Rat	54
19 Lym-3	Lymphosarcoma	Rat	54
19 Pr-19	Prostatic Fibroadenoma	Rat	55
20 Pr-1	Prostatic Fibroadenoma	Rat	55
20 Lym-3	Lymphosarcoma	Rat	55
21 Pr-9	Prostatic Carcinoma	Rat	55
22 Pr-8	Prostatic Adenocarcinoma	Rat	55
23 Pr-7	Prostatic Carcinoma	Rat	55
24 Pr-2	Prostatic Carcinoma	Rat	55
25 Pr-3	Prostatic Adenocarcinoma	Rat	55
A1011	Unknown	Rat	48
A1131-AR	Unknown	Rat	48
A1138-AL	Unknown	Rat	48
A1140-CL-10	Unknown	Rat	48
A2780	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
A498	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	57
A546 (DMBZ)		Rat	48
A549	Nonsmall Cell	Human <i>In Vitro</i> Cell Lines	57
A704	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	57
A920 (Tetramin)		Rat	48

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
AA Ascites	Spontaneous Ascites	Rat	48
ACHN	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	57
Adenocarcinoma 755 (CA755, Bagg-Jackson, Adenocarcinoma)	Mammary Adenocarcinoma	Mouse	30
ADJ-PC-6	Plasmacytoma	Mouse	30
ASB XIV	Pulmonary Squamous Cell Carcinoma	Mouse	30
AT	Adrenal	Mouse	30
ATC 64	Thyroid Carcinoma	Rat	48
AtT/20	Anterior Pituitary	Mouse	30
Attenuated Resistant	Unknown	Rat	48
B16	Melanoma (amelanotic)	Jackson Lab Mouse	43
B16BL-6	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	65
B16F ¹	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	65
B16F ¹⁰	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	65
B16F ^{L6}	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	65
BALB/c 3T3	Normal	NonHuman <i>In Vitro</i> Cell Lines	65
BL12 Sensitive	Lymphosarcoma	Mouse	30
BL12/Hc Ra	Lymphosarcoma	Mouse	30
BOW-G	Melanosarcoma	Human	15
Brown-Pearce	Carcinoma (Epithelioma)	Rabbit	46
BT/M520	Fibrosarcoma	Rat	48
BT-549	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
BW10232	Mammary Adenocarcinoma	Mouse	30
BW10232	Mammary Adenocarcinoma	Jackson Lab Mouse	43
BW7756	Hepatoma	Mouse	30
BW7756	Hepatoma	Jackson Lab Mouse	43
BW8685	Pituitary	Mouse	30
BW8685	Pituitary	Jackson Lab Mouse	44
BW8883	Pituitary	Mouse	30
BW8883	Pituitary	Jackson Lab Mouse	43
C1300	Round Cell (Neuroblastoma?)	Jackson Lab Mouse	44
C1498	Myelogenous Leukemia	Mouse	30
C1498	Myeloid Leukemia	Jackson Lab Mouse	43
C3HBA	Mammary Adenocarcinoma	Mouse	30
C3HBA	Mammary Adenocarcinoma	Jackson Lab Mouse	43
C3HIOT ½		NonHuman <i>In Vitro</i> Cell Lines	65
C4461	Lung Adenocarcinoma	Mouse	30
C58/J Spontaneous	Leukemia	Mouse	30
C95 Spleen/R		Mouse	30
CA 20948	Pancreatic Acinar Carcinoma	Rat	48
CA07/A	Colon Adenocarcinoma	Mouse	30
CA36/Ara C (NSC-63878)	Colon Adenocarcinoma	Mouse	30
CA51	Colon Adenocarcinoma	Mouse	30
CaD1	Mammary Adenocarcinoma	Mouse	30
CaD1	Mammary Adenocarcinoma	Jackson Lab Mouse	43
CaD2	Mammary Adenocarcinoma	Mouse	31

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
CAKI-1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	57
Carcinosarcoma	Carcinosarcoma (skin) (18-day embryos)	Rat	48
CCO 1865	Mesothelioma	Rat	48
CCO/1923	Hemangiosarcoma	Mouse	31
CCRF-GEM	Leukemia	Human <i>In Vitro</i> Cell Lines	57
CCRF-SB	Leukemia	Human <i>In Vitro</i> Cell Lines	57
CE1460 MACA	Mammary Adenocarcinoma	Mouse	31
Cell Sarcoma		Mouse	34
CH	Mammary Adenocarcinoma	Mouse	31
CHA-59	Bone, Osteosarcoma	Human	57
CHO 1C T6	Normal	NonHuman <i>In Vitro</i> Cell Lines	65
Cloudman Melanoma	Melanoma	Mouse	31
COLO 205	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
Colon 26 (C26)	Carcinoma	Mouse	31
Colon 26	Carcinoma	NonHuman <i>In Vitro</i> Cell Lines	65
Colon 38	Carcinoma	Mouse	31
COO-G	Mammary Carcinoma	Human	13
COS-G	Lung, Papillary Carcinoma	Human	13
Crocker Sarcoa		Mouse	31
CSE	Fibrosarcoma	Rat	48
CWR-22	Prostate, Adenocarcinoma	Human	17
CX-1 (HT-29)	Colon, Adenocarcinoma	Human	14
CX-2	Colon, Carcinoma	Human	14
CX-3	Colon, Carcinoma	Human	14
CX-5	Colon, Adenocarcinoma	Human	14
D1T10		Mouse	31
DAU	Burkitt's Lymphoma	Human	17
DBA/2 Spontaneous Tumor M114	Mammary Adenocarcinoma	Mouse	31
dbrB	Anaplastic Carcinoma	Mouse	31
dbrB	Anaplastic Carcinoma	Jackson Lab Mouse	43
DDB81-23	T cell Lymphoma	Rat	48
DEAC-1	Mucoepidermoid Carcinoma	Human	17
DEAC-7	Melanoma	Human	15
DEL-G	Sarcoma	Human	17
DL Wells-17	T cell Lymphoma	Rat	48
DMBA	Mammary Adenocarcinoma	Rat	48
DMS-114	Small Cell	Human <i>In Vitro</i> Cell Lines	57
DSL62-38	Pancreatic Tumor	Rat	48
DU-145	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
DU4475	Mammary Carcinoma	Human	13
Dunning Leukemia	Atypical Monocytic Leukemia	Rat	48
Dunning Leukemia/ NSC-10107 (nitromin)	Atypical Monocytic Leukemia	Rat	48
Dunning Leukemia/ NSC-13875 (HMM)	Atypical Monocytic Leukemia	Rat	48

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
Dunning Leukemia/ NSC-17261 (benzoquinone)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ NSC-23892 (dimethylbenzimidazole)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ NSC-26980 (mitomycin C)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ NSC-29422 (thioguanosine)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ NSC-3088 (chlorambucil)	Atypical Monocytic Leukemia	Rat	48
Dunning Leukemia/ NSC-45059 (o-acetyltetramin)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ NSC-51845 (cyclohexylamine)	Atypical Monocytic Leukemia	Rat	49
Dunning Leukemia/ 755 (6-MP)	Atypical Monocytic Leukemia	Rat	48
E Male Gross	Leukemia	Mouse	31
Egg/Mouse Leukemia	Lymphocytic Leukemia	Mouse	31
Ehrlich Ascites	Mammary Adenocarcinoma	Mouse	31
Ehrlich Ascites, Tetraploid	Mammary Adenocarcinoma	Mouse	31
Ehrlich Ascites/6-TG (NSC-752)	Mammary Adenocarcinoma	Mouse	31
EKVX	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
EL-4	Lymphoma	NonHuman <i>In Vitro</i> Cell Lines	65
EL-4 Male	Lymphoma	Mouse	31
ELL-G	Mammary Carcinoma	Human	13
EMT-6	Mammary Adenocarcinoma	Mouse	31
Ependymblastoma (Zimmerman)	Ependymblastoma	Mouse	31
FB SAR (A)	Fibrosarcoma	Mouse	31
FB SAR (B)	Fibrosarcoma	Mouse	31
FBL-3	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	65
FCB (C)	Transitional Cell Carcinoma of the Bladder	Mouse	32
Fibrosarcoma	Fibrosarcoma	Hamster	19
Flexner-Jobling	Seminal Vesicle Adenocarcinoma	Rat	49
FO #1	Melanoblastoma	Human	15
Fran Tumor	Ovarian Carcinoma	Rat	49
Friend Virus Leukemia (FV01)	Reticulum Cell Sarcoma	Mouse	32
Furth Tumor		Mouse	32
FV01		Mouse	32
Gardner Lymphosarcoma		Mouse	32
GBT/W	Glial Tumor	Rat	49
GL-1		Mouse	32
Glioma 26	Glioma	Mouse	32
Glioma 261	Glioma	Mouse	32
GOB-G	Colon, Adenocarcinoma	Human	14
Gross Leukemia	Leukemia	Mouse	32
Gross Mammary Adenocarcinoma	Mammary Adenocarcinoma	Mouse	32
Guinea Pig Line 1 GP1	Hepatocarcinoma	Guinea Pig	21
Guinea Pig Line 1 GP10	Hepatocarcinoma	Guinea Pig	21

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
H-12	Mesothelioma	Hamster	19
H23 (NCI-H23)	Lung, Nonsmall Cell, Adenocarcinoma	Human	14
H2712	Mammary Adenocarcinoma	Mouse	32
H2712	Mammary Adenocarcinoma	Jackson Lab Mouse	43
H-372	Leydig	Rat	49
H460 (NCI-H460)	Lung, Nonsmall Cell, Epid.	Human	14
H-540	Leydig	Rat	49
H6	Hepatoma	Mouse	32
H6	Hepatoma	Jackson Lab Mouse	43
H-75	Mesothelioma	Hamster	19
Hageman		Mouse	32 or 38?
Harding-Passey	Melanoma	Mouse	32
Hauschka Ascites Tumor	Unknown	Mouse	32
HB Lynch-Fibroma 522	Fibroma	Rat	49
HCC-2998	Colorectal Carcinoma	Human	14
HCC-2998	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
HCT-116	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
HCT-15	Colon, Carcinoma	Human	14
HCT-15	Carcinoma	Human <i>In Vitro</i> Cell Lines	57
HE10734	Osteogenic Sarcoma	House	32
HE10734/FR	Osteogenic Sarcoma	House	32
HELA	Carcinoma	Human <i>In Vitro</i> Cell Lines	57
HEP-3	Epidermoid Carcinoma	Human	17
Hepatoma 129 (HE129)	Hepatoma	Mouse	32
Hepatoma 134 (HE134, Shear Hepatoma 134)	Hepatoma	Mouse	32
Hepatoma NK		Rat	49
HIG-G	Mammary Carcinoma	Human	13
HL-3	Lymphoma	Human <i>In Vitro</i> Cell Lines	57
HL-4	Lymphoma	Human <i>In Vitro</i> Cell Lines	57
HL-60	Pro-myelocytic Leukemia	Human <i>In Vitro</i> Cell Lines	57
HMC	Histiocytoma	Rat	49
H-MESO-1	Lung, Mesothelioma	Human	14
H-MESO-1	Mesothelioma	Human <i>In Vitro</i> Cell Lines	57
H-MESO-1A	Lung, Mesothelioma	Human	14
HOP-18	Large Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	57
HOP-62	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
HOP-92	Large Cell	Human <i>In Vitro</i> Cell Lines	57
HP	Amelanotic Melanoma	Mouse	32
HP	Melanoma (Amelanotic)	Jackson Lab Mouse	43
HS 578T	Adenocarcioma	Human <i>In Vitro</i> Cell Lines	57
HS 913T	Mixed Cell	Human <i>In Vitro</i> Cell Lines	57
HS-1	Sarcoma	Human	17
HT-29	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
IGR-OV1	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	57
IRS 9802	Spindle Cell Sarcoma	Rat	49

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
Islet Cell	Pancreatic Adenocarcinoma	Hamster	19
J-30237	Unknown	Mouse	32
K-1735	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	65
K-562	Leukemia	Human <i>In Vitro</i> Cell Lines	58
KB-ADL #12	Epidermoid	Human <i>In Vitro</i> Cell Lines	58
Kid-27B	Kidney Adenocarcinoma	Rat	53
Klein Tumor (TA3)	Mammary Adenocarcinoma	Mouse	32
KLO-G	Colon, Adenocarcinoma	Human	14
KM 20L2 (derivative of HT-29)	Colon, Adenocarcinoma	Human	14
KM 20L2 (derivative of HT-29)	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
KM-12	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
Krebs 2 Carcinoma	Carcinoma of Inguinal Region	Mouse	32
Krebs Ascites		Mouse	32
L.T.W. (Furth)	Leydig	Rat	49
L1210	Lymphoid Leukemia	Mouse	32
L1210 FR3 DCM/R 100a	Lymphoid Leukemia	Mouse	34
L1210 Variants		Mouse	34
L1210/5FU (NSC-19893)	Lymphoid	Mouse	33
L1210/6MP (NSC-755)	Lymphoid Leukemia	Mouse	33
L1210/6MP/6TG	Lymphoid Leukemia	Mouse	34
L1210/Anhydro-Ara C (NSC-145668)	Lymphoid Leukemia	Mouse	33
L1210/Ara-C (NSC-63878)	Lymphoid Leukemia	Mouse	33
L1210/BCNU (NSC-409962)	Lymphoid Leukemia	Mouse	33
L1210/C95	Lymphoid Leukemia	Mouse	33
L1210/cis-DDP (NSC-119875)	Lymphoid Leukemia	Mouse	33
L1210/CTX (NSC-26271)	Lymphoid Leukemia	Mouse	33
L1210/DF8 (NSC-29630)	Lymphoid Leukemia	Mouse	33
L1210/DTIC (NSC-45388)	Lymphoid Leukemia	Mouse	33
L1210/FR8 (Folate Reductase)	Lymphoid Leukemia	Mouse	34
L1210/FR8/DCM	Lymphoid Leukemia	Mouse	34
L1210/Ftorafur (NSC-148958)	Lymphoid Leukemia	Mouse	34
L1210/HU (NSC-32065)	Lymphoid Leukemia	Mouse	33
L1210/L-PAM (NSC-8806)	Lymphoid Leukemia	Mouse	33
L1210/M-773	Lymphoid Leukemia	Mouse	34
L1210/MeGAG (NSC-32946)	Lymphoid Leukemia	Mouse	33
L1210/MRI (NSC-153353)	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	65
L1210/MTX (NSC-740)	Lymphoid Leukemia	Mouse	33
L1210/NSC-19622	Lymphoid Leukemia	Mouse	33
L1210/NSC-38280	Lymphoid Leukemia	Mouse	33
L1210/TIC (NSC-60339)	Lymphoid Leukemia	Mouse	33
L1210/TSC (NSC-729)	Lymphoid Leukemia	Mouse	33
L18464	Lymphoma	Mouse	34
L4946	Lymphocytic Leukemia	Mouse	34
L5178Y	Leukemia	Mouse	34
L5178Y (R)/MRI	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	65

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
LAF ₁	Adrenal Cortical Adenocarcinoma	Mouse	34
LC-12	Pulmonary Squamous Cell Carcinoma	Mouse	34
LC-18	Hepatocarcinoma	Rat	49
Lewis Lung	Carcinoma	Mouse	34
Lewis Lung	Carcinoma	NonHuman <i>In Vitro</i> Cell Lines	65
Lewis Lung/PALA (NSC-224131)	Carcinoma	Mouse	34
Lewis Sarcoma T241	Pleiomorphic	Mouse	34
Line 1	Hepatocarcinoma	Guinea Pig	21
Line 10	Hepatocarcinoma	Guinea Pig	21
LOVO	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
LOVO I	Colon, Adenocarcinoma	Human	14
LOVO II	Colon, Adenocarcinoma	Human	15
LOX IMVI	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	58
LPC-1	Plasmacytoma	Mouse	35
LS402AX	Teratosarcoma	Mouse	35
LSTRA	Lymphosarcoma	Mouse	35
LSTRA/DTIC (NSC-45388)	Lymphosarcoma	Mouse	35
LX-1	Lung, Undifferentiated Carcinoma	Human	13
LXFL 529	Large Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	58
Lymphoma 8	Lymphoma	Rat	49
Lymphosarcoma	Lymphosarcoma	Hamster	19
M14	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	58
M19-MEL	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	58
M4898	Lung Adenocarcinoma	Mouse	35
M5076	Reticulum Cell Sarcoma	Mouse	35
M5076	Reticulum Cell Sarcoma	NonHuman <i>In Vitro</i> Cell Lines	65
M5076/cis-DDP (NSC-119875)	Reticulum Cell Sarcoma	Mouse	35
M5076/HMM (NSC-13875)	Reticulum Cell Sarcoma	Mouse	35
M5076/L-PAM (NSC-8806)	Reticulum Cell Sarcoma	Mouse	35
M5480	Testicular Carcinoma (Seminoma)	Mouse	35
MA13C	Mammary Adenocarcinoma	Mouse	35
MA16C	Mammary Adenocarcinoma	Mouse	35
MA387	Fusiform Cell Sarcoma	Mouse	35
MADB 106		NonHuman <i>In Vitro</i> Cell Lines	65
MADB 200		NonHuman <i>In Vitro</i> Cell Lines	65
Madison Lung (TA109)	Carcinoma	Mouse	35
MALME-3M	Melanoma	Human <i>In Vitro</i> Cell Lines	58
MAMF2-TC	Fibrosarcoma	Rat	49
Mastocytoma		Mouse	32
MC-11	Mammary Adenocarcinoma	Mouse	35
MC-5	Mammary Adenocarcinoma	Mouse	35
MC-6 Female	Mammary Adenocarcinoma	Mouse	35
MCF7	Mammary Carcinoma	Human	13
MCF7	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
MCS-1	Mammary Adenocarcinoma	Mouse	35

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
MDA-MB-231	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
MDA-MB-435	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
MDA-MB-436	Mammary Carcinoma	Human	13
Mecca (ME61, MLS)	Lymphosarcoma	Mouse	35
Melanoma	Melanotic Melanoma	Hamster	19
MET 149-2	Adenocarcinoma	Rat	49
METH-A	Sarcoma	Mouse	35
MLS		Mouse	35
MNU-Buffalo	Mammary Carcinoma	Rat	50
Moloney Sarcoma (SV-122-TR4)	Sarcoma	Mouse	35
MOLT-4	Leukemia	Human <i>In Vitro</i> Cell Lines	58
Moore Sarcoma #1	Sarcoma	Rat	49
MOPC-104	Plasmacytoma	Mouse	36
MOPC-112	Plasmacytoma	Mouse	36
MOPC-113	Plasmacytoma	Mouse	36
MOPC-114	Plasmacytoma	Mouse	36
MOPC-116	Plasmacytoma	Mouse	36
MOPC-118	Plasmacytoma	Mouse	36
MOPC-121	Plasmacytoma	Mouse	37
MOPC-123	Plasmacytoma	Mouse	37
MOPC-129	Plasmacytoma	Mouse	37
MOPC-132	Plasmacytoma	Mouse	36
MOPC-140	Plasmacytoma	Mouse	36
MOPC-141	Plasmacytoma	Mouse	36
MOPC-157	Plasmacytoma	Mouse	36
MOPC-17	Plasmacytoma	Mouse	35
MOPC-172	Plasmacytoma	Mouse	36
MOPC-173	Plasmacytoma	Mouse	36
MOPC-209	Plasmacytoma	Mouse	36
MOPC-21	Plasmacytoma	Mouse	35
MOPC-28	Plasmacytoma	Mouse	35
MOPC-30	Plasmacytoma	Mouse	35
MOPC-31	Plasmacytoma	Mouse	35
MOPC-4	Plasmacytoma	Mouse	35
MOPC-41	Plasmacytoma	Mouse	35
MOPC-46	Plasmacytoma	Mouse	35
MOPC-47	Plasmacytoma	Mouse	35
MOPC-48	Plasmacytoma	Mouse	36
MOPC-49	Plasmacytoma	Mouse	36
MOPC-51	Plasmacytoma	Mouse	36
MOPC-61	Plasmacytoma	Mouse	36
MOPC-63	Plasmacytoma	Mouse	36
MOPC-67	Plasmacytoma	Mouse	36
MOPC-69	Plasmacytoma	Mouse	36
MOPC-70	Plasmacytoma	Mouse	36

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
MOPC-78	Plasmacytoma	Mouse	36
MOPC-88	Plasmacytoma	Mouse	36
MOPC-91	Plasmacytoma	Mouse	36
MOPC-96	Plasmacytoma	Mouse	36
Morris Hepatomas	Hepatoma	Rat	50
MPC-1	Plasmacytoma	Mouse	37
MPC-11	Myeloma	NonHuman <i>In Vitro</i> Cell Lines	65
MPC-15	Plasmacytoma	Mouse	37
MPC-2	Plasmacytoma	Mouse	37
MPC-25	Plasmacytoma	Mouse	37
MPC-26	Plasmacytoma	Mouse	37
MPC-31	Plasmacytoma	Mouse	37
MPC-36	Plasmacytoma	Mouse	37
MPC-37	Plasmacytoma	Mouse	37
MPC-40	Plasmacytoma	Mouse	37
MPC-42	Plasmacytoma	Mouse	37
MPC-44	Plasmacytoma	Mouse	37
MPC-48	Plasmacytoma	Mouse	37
MPC-49	Plasmacytoma	Mouse	37
MPC-59	Plasmacytoma	Mouse	37
MPC-60	Plasmacytoma	Mouse	37
MPC-63	Plasmacytoma	Mouse	37
MPC-64	Plasmacytoma	Mouse	37
MPC-67	Plasmacytoma	Mouse	37
MPC-73	Plasmacytoma	Mouse	37
MPC-H	Plasmacytoma	Mouse	38
MRI-H-121	Kidney, Carcinoma	Human	16
MRI-H-121B	Melanoma, Malignant	Human	15
MRI-H-130	Cervix, Squamous Cell Carcinoma	Human	15
MRI-H-147	Endometrium, Carcinoma, Müllerian Duct	Human	16
MRI-H-1579	Prostate Adenocarcinoma	Human	17
MRI-H-165	Lung, Squamous Cell Carcinoma	Human	14
MRI-H-166	Kidney, Transitional Cell Carcinoma	Human	16
MRI-H-171	Endometrium, Carcinoma	Human	16
MRI-H-177	Cervix, Squamous Cell Carcinoma	Human	15
MRI-H-1834	Ovarian Carcinoma	Human	16
MRI-H-186	Cervix, Invasive, Large Cell, Nonkeratinizing, Squamous Cell Carcinoma	Human	15
MRI-H-187	Melanoma, Epitheloid, Melanotic	Human	15
MRI-H-194	Colon, Adenocarcinoma	Human	14
MRI-H-196	Cervix, Poorly Differentiated Squamous Cell Carcinoma	Human	15
MRI-H-207	Ovary, Undifferentiated Carcinoma	Human	16
MRI-H-215	Cervix, Invasive, Large Cell, Nonkeratinizing, Poorly Differentiated, Epidermoid Carcinoma	Human	16
MRI-H-220	Endometrium, Carcinoma	Human	16

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
MRI-H-221	Melanoma, Malignant	Human	15
MRI-H-227	Ovarian Adenocarcinoma	Human	16
MRI-H-250	Colon, Carcinoma	Human	15
MRI-H-253	Endometrium, Carcinoma	Human	16
MRI-H-254	Stomach, Adenocarcinoma	Human	17
MRI-H-255	Melanoma	Human	15
MRI-H-258	Ovarian Adenocarcinoma	Human	16
MRI-H-266	Lung, Poorly Differentiated Carcinoma	Human	14
MRI-H-273	Ovarian Carcinoma	Human	16
MS-2	Sarcoma	Mouse	38
MST	Mast Cell	Mouse	38
MT/W449	Mammary Adenocarcinoma	Rat	50
MT/W9	Mammary Adenocarcinoma	Rat	50
MtT	Anterior Pituitary	Rat	50
Murphy-Sturm Lymphosarcoma (MSL)	Lymphosarcoma	Rat	50
MX-1	Mammary Carcinoma	Human	13
MX-1	Carcinoma	Human <i>In Vitro</i> Cell Lines	58
MX-2	Mammary Carcinoma	Human	13
MXT	Mammary Ductal	Mouse	38
NBW-37	T Cell Lymphoma	Rat	50
NC-37	Normal	Human <i>In Vitro</i> Cell Lines	58
NCI/ADR-RES	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59
NCI-H125	Adenosquamous Carcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H226	Squamous Cell	Human <i>In Vitro</i> Cell Lines	58
NCI-H23	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H292	Adenosquamous Carcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H322M	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H358M	Bronchiolo-Alveolar Carcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H460	Large Cell	Human <i>In Vitro</i> Cell Lines	58
NCI-H522	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H69	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	58
NCI-H82	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	58
Nettesheim Lung	Squamous Cell Lung Carcinoma	Mouse	38
NIS-G	Melanosarcoma	Human	15
Nitrosamine-Induced Hepatoma	Hepatoma	Guinea Pig	21
NK-Lymphoma	Lymphoma	Mouse	38
Novikoff Hepatoma	Hepatoma	Rat	50
NS104	Rhabdomyosarcoma	Rat	50
OGL-G	Sarcoma, Spindle Cell, Periosteal Osteogenic	Human	17
OR-16-3	Thymus Tumor	Rat	50
OV		Human <i>In Vitro</i> Cell Lines	59
OVCAR-3	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59
OVCAR-4	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59
OVCAR-5	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59
OVCAR-8	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
P1534	Lymphocytic Leukemia	Mouse	39
P1798	Lymphosarcoma	Mouse	39
P1798/CR-JS	Lymphoma	Mouse	39
P1798/CS-JS	Lymphoma	Mouse	39
P288	Lymphocytic Leukemia	Mouse	38
P288/MTX (NSC-740)	Lymphocytic Leukemia	Mouse	38
P388	Lymphocytic Leukemia	Mouse	38
P388	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	65
P388/5-Azacytidine (NSC-102816)	Lymphocytic Leukemia	Mouse	38
P388/5FU (NSC-19893)	Lymphocytic Leukemia	Mouse	38
P388/Acivicin (NSC-163501)	Lymphocytic Leukemia	Mouse	39
P388/ActinomycinD (NSC-3053)	Lymphocytic Leukemia	Mouse	38
P388/ADR (NSC 123127)	Lymphocytic Leukemia	Mouse	38
P388/Amsacrine (NSC-249992)	Lymphocytic Leukemia	Mouse	39
P388/Ara-A + 2'dcF (NSC-404241 + NSC-218321)	Lymphocytic Leukemia	Mouse	39
P388/Ara-C (NSC-63878)	Lymphocytic Leukemia	Mouse	38
P388/BCNU (NSC-409962)	Lymphocytic Leukemia	Mouse	39
P388/CPA (NSC-26271)	Lymphocytic Leukemia	Mouse	38
P388/Daunomycin (NSC-82151)	Lymphocytic Leukemia	Mouse	38
P388/DON (NSC-7365)	Lymphocytic Leukemia	Mouse	38
P388/L-Alanosine (NSC-153353)	Lymphocytic Leukemia	Mouse	39
P388/L-PAM (NSC-8806)	Lymphocytic Leukemia	Mouse	38
P388/Mitoxantrone (NSC-301739)	Lymphocytic Leukemia	Mouse	39
P388/MTX (NSC-740)	Lymphocytic Leukemia	Mouse	38
P388/VCR (NSC-67574)	Lymphocytic Leukemia	Mouse	38
P3X63		NonHuman <i>In Vitro</i> Cell Lines	65
P815 (Hageman Mastocytoma)	Mast Cell Leukemia	Mouse	39
P815/VLB (NSC-49842)	Mast Cell Leukemia	Mouse	39
Pan #1 (Fortner)	Pancreatic Duct Adenocarcinoma	Hamster	19
PAN 02	Pancreas	Mouse	39
PAN 02	Adenocarcinoma	NonHuman <i>In Vitro</i> Cell Lines	65
PAN 03	Pancreas	Mouse	39
Papillary Carcinoma		Mouse	38
PC-3	Carcinoma	Human <i>In Vitro</i> Cell Lines	59
PC-3/M	Carcinoma	Human <i>In Vitro</i> Cell Lines	59
PR1C1T5/NSC-45388	Lymphoid Leukemia	Mouse	39
PR1SE1T5	Lymphoid Leukemia	Mouse	39
PR1SE1T5/NSC-45388	Lymphoid Leukemia	Mouse	39
R-26	Unknown	Mouse	39
R3149	Leukemia	Rat	51
R3230AC	Mammary Adenocarcinoma	Rat	51
R3259	Giant Cell Sarcoma	Rat	50
R3327	Prostate	Rat	51
R3327 (Pap)	Prostate	Rat	51
R35	Mammary Adenocarcinoma	Rat	50

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
R-46	Unknown	Mouse	39
R-53	Unknown	Mouse	39
R-74	Unknown	Mouse	40
RBL-5 (Rauscher Virus Induced Transplantable Tumor-5)	Leukemia	Mouse	40
RC-2	Renal Adenocarcinoma	Mouse	40
Reif-Allen Tumor	Thymoma	Mouse	40
Rice 500	Leydig	Rat	50
Rice D6	Leydig	Rat	50
Riejoel	Thyroid Adenocarcinoma	Rat	50
RNC 259	Pheochromocytoma	Rat	50
RNC 288	Insulinoma	Rat	50
RNK-16	LGL Leukemia	Rat	51
RPC-20	Plasmacytoma	Mouse	40
RPC-5	Plasmacytoma	Mouse	40
RPC-9	Plasmacytoma	Mouse	40
RPMI-7951	Melanoma	Human <i>In Vitro</i> Cell Lines	59
RPMI-8226	Leukemia	Human <i>In Vitro</i> Cell Lines	59
RXF 393 (available only to DTP, NCI)	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
RXF 631	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
S180	Pleomorphic Sarcoma	Jackson Lab Mouse	44
S180 (Crocker, S III)	Pleomorphic Cell	Mouse	40
S37	Pleomorphic Cell	Mouse	40
S37	Pleomorphic Sarcoma	Jackson Lab Mouse	44
S91	Melanoma (Melanotic)	Jackson Lab Mouse	43
Sa 1	Spindle Cell Carcinoma	Mouse	40
Sa D2	Fibrosarcoma	Mouse	40
Sa D2	Fibrosarcoma	Jackson Lab Mouse	43
Sal	Spindle-Cell Sarcoma	Jackson Lab Mouse	44
Sarcoma		Mouse	40
Sarcoma		Mouse	40
SB #1 (Fortner)	Small Bowel Adenocarcinoma	Hamster	19
SF 295	Glioblastoma	Human	17
SF-268	Glioblastoma	Human <i>In Vitro</i> Cell Lines	59
SF-295	Glioblastoma	Human <i>In Vitro</i> Cell Lines	59
SF-539	Glioblastoma	Human <i>In Vitro</i> Cell Lines	59
Shay Leukemia	Myelogenous Leukemia	Rat	51
Shear Hepatoma 134		Mouse	40
SHP-77	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SJL/JW	Reticulum Cell Sarcoma	Mouse	40
SK-MEL-2	Melanoma	Human <i>In Vitro</i> Cell Lines	59
SK-MEL-28	Melanoma	Human <i>In Vitro</i> Cell Lines	59
SK-MEL-5	Melanoma	Human <i>In Vitro</i> Cell Lines	59
SK-MES-1	Squamous Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SK-OV-3	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	59

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
SMT-2A	Mammary Carcinoma	Rat	51
SN12A1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SN12C	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SN12L1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SN21S1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SN12K1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	59
SNB-19	Glioblastoma	Human <i>In Vitro</i> Cell Lines	59
SNB-7	Glioblastoma	Human <i>In Vitro</i> Cell Lines	59
SNB-75	Glioblastoma	Human <i>In Vitro</i> Cell Lines	60
SNB-78	Astrocytoma	Human <i>In Vitro</i> Cell Lines	60
Spontaneous Mammary	Mammary Adenocarcinoma	Mouse	40
Spontaneous Adrenal	Adrenal	Mouse	40
Spontaneous DBA/2 Mammary	Mammary Adenocarcinoma	Mouse	40
SR	Lymphoma	Human <i>In Vitro</i> Cell Lines	60
SV-122-TR4		Mouse	40
SW-613	Mammary Carcinoma	Human	13
SW-620		Human <i>In Vitro</i> Cell Lines	60
SWA-G	Ovarian Carcinoma	Human	16
Swarm	Chondrosarcoma	Rat	51
T1699	Mammary Adenocarcinoma	Mouse	40
T1699	Mammary Adenocarcinoma	Jackson Lab Mouse	43
T1703	Mammary Adenocarcinoma	Mouse	40
T1703	Mammary Adenocarcinoma	Jackson Lab Mouse	43
T-47D (not to or for commercial use)	Mammary	Human <i>In Vitro</i> Cell Lines	60
TA109		Mouse	40
TA3		Mouse	40
TG1-4	Mesothelioma	Hamster	19
TK-10	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	60
TR.CLXXXVIII	Melanoma	Rat	51
TR.DCCXLIII	Pituitary	Rat	51
TRI-G	Melanoma	Human	15
TS1-4	Epidermoid Carcinoma	Hamster	19
U-251	Glioblastoma	Human <i>In Vitro</i> Cell Lines	60
UACC-257	Melanoma	Human <i>In Vitro</i> Cell Lines	60
UACC-62	Melanoma	Human <i>In Vitro</i> Cell Lines	60
UCSD 242L	Melanoma	Human <i>In Vitro</i> Cell Lines	60
UCSD 354L	Melanoma	Human <i>In Vitro</i> Cell Lines	60
UO-31	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	60
UV-2237	Fibrosarcoma	NonHuman <i>In Vitro</i> Cell Lines	65
VAN-G	Mammary Carcinoma	Human	13
VX-2 (V2)	Skin Carcinoma	Rabbit	46
Walker 256	Carcinosarcoma	Rat	51
WIDR (derivative of HT-29)	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	60
WIL-G	Melanoma	Human	15
X5563	Unknown	Mouse	40

ALPHABETICAL TUMOR INDEX

Designation	Histologic Type	Species	Page No.
XF 498	Glioblastoma	Human <i>In Vitro</i> Cell Lines	60
YAC	Lymphoma	NonHuman <i>In Vitro</i> Cell Lines	65
Yoshida Hepatoma	Hepatoma	Rat	51
Yoshida Sarcoma	Sarcoma	Rat	51
YPC-1	Plasmacytoma	Mouse	40
Zimmerman Ependymoblastoma		Mouse	41